<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">evrazkar</journal-id><journal-title-group><journal-title xml:lang="ru">Евразийский Кардиологический Журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Eurasian heart journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2225-1685</issn><issn pub-type="epub">2305-0748</issn><publisher><publisher-name>Евразийская ассоциация кардиологов</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.38109/2225-1685-2021-4-6-59</article-id><article-id custom-type="elpub" pub-id-type="custom">evrazkar-6289</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL GUIDELINES</subject></subj-group></article-categories><title-group><article-title>Евразийские клинические рекомендации по диагностике и лечению острого коронарного синдрома без подъема сегмента ST (ОКСбпST)</article-title><trans-title-group xml:lang="en"><trans-title>Eurasian clinical guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome (NSTE-ACS)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4642-3610</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Барбараш</surname><given-names>О. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Barbarash</surname><given-names>O. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p> член-корр. РАН, д.м.н., профессор, директор</p><p>Кемерово </p></bio><bio xml:lang="en"><p> Corresponding Member RAS, Dr. of Sci. (Med.), Professor, Director</p><p>Kemerovo </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9141-103X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Комаров</surname><given-names>А. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Komarov</surname><given-names>A. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д.м.н., ведущий научный сотрудник отдела клинических проблем атеротромбоза института клинической кардиологии  им. А.Л. Мясникова</p><p>Москва </p></bio><bio xml:lang="en"><p> Dr. of Sci. (Med.), Leading Researcher, Department of Clinical Problems of Atherothrombosis, Institute of Clinical Cardiology</p><p>Moscow </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9158-2522</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Панченко</surname><given-names>Е. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Panchenko</surname><given-names>E. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д.м.н., профессор, руководитель отдела клинических проблем атеротромбоза института клинической кардиологии им. А.Л. Мясникова</p><p>Москва </p></bio><bio xml:lang="en"><p> Dr. of Sci. (Med.), Professor, Head of the Department of Clinical Problems of Atherothrombosis, Institute of Clinical Cardiology</p><p>Moscow </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0049-6101</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Староверов</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Staroverov</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д.м.н., профессор, главный научный сотрудник, руководитель отдела неотложной кардиологии института клинической кардиологии им. А.Л. Мясникова</p><p>Москва </p></bio><bio xml:lang="en"><p> Dr. of Sci. (Med.), Professor, Chief Researcher, Head of the Department of Emergency Cardiology, Institute of Clinical Cardiology</p><p>Moscow </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3248-0224</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шахнович</surname><given-names>Р. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Shahnovich</surname><given-names>R. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д.м.н., профессор, ведущий научный сотрудник отдела неотложной кардиологии института клинической кардиологии им. А.Л. Мясникова</p><p> 121552, Москва, ул. 3-я Черепковская, д. 15а</p></bio><bio xml:lang="en"><p> Dr. of Sci. (Med.), Professor, Leading Researcher of the Department of Emergency Cardiology, Institute of Clinical Cardiology</p><p>Moscow </p></bio><email xlink:type="simple">shakhnovich@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2816-1183</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Явелов</surname><given-names>И. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Yavelov</surname><given-names>I. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д.м.н., профессор, ведущий научный сотрудник отдела клинической кардиологии и молекулярной генетики</p><p>Москва </p></bio><bio xml:lang="en"><p> Dr. of Sci. (Med.), Professor, Leading Researcher, Department of Clinical Cardiology and Molecular Genetics</p><p>Moscow </p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute for Complex Problems of Cardiovascular Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «НМИЦ Кардиологии» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center of Cardiology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУ «НМИЦ профилактической медицины» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center of Preventive Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>25</day><month>11</month><year>2021</year></pub-date><volume>0</volume><issue>4</issue><fpage>6</fpage><lpage>59</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Барбараш О.Л., Комаров А.Л., Панченко Е.П., Староверов И.И., Шахнович Р.М., Явелов И.С., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Барбараш О.Л., Комаров А.Л., Панченко Е.П., Староверов И.И., Шахнович Р.М., Явелов И.С.</copyright-holder><copyright-holder xml:lang="en">Barbarash O.L., Komarov A.L., Panchenko E.P., Staroverov I.I., Shahnovich R.M., Yavelov I.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.heartj.asia/jour/article/view/6289">https://www.heartj.asia/jour/article/view/6289</self-uri><abstract><p> </p><p>Рекомендации ЕАК отражают точку зрения ЕАК и были подготовлены после тщательного изучения научных и медицинских данных, имеющихся на момент их публикации. ЕАК не несут ответственности в случае какого-либо противоречия, несоответствия и / или неоднозначности между Рекомендациями ЕАК и любыми другими официальными рекомендациями или руководствами, выпущенными соответствующими органами общественного здравоохранения, в частности, в отношении правильного использования медицинских или терапевтических стратегий. Медицинским работникам рекомендуется в полной мере учитывать Рекомендации ЕАК при оценке своего клинического суждения, а также при определении и реализации профилактических, диагностических или терапевтических медицинских стратегий. Тем не менее, Рекомендации ЕАК никоим образом не отменяют индивидуальную ответственность медицинских работников за принятие надлежащих и точных решений с учетом состояния здоровья каждого пациента и в консультации с этим пациентом и, при необходимости и / или необходимости, опекуна пациента. Рекомендации ЕАК не освобождают медицинских работников от полного и тщательного рассмотрения соответствующих официальных обновленных рекомендаций или руководств, выпущенных компетентными органами общественного здравоохранения, для рассмотрения каждого медицинского случая в свете современных научно обоснованных рекомендаций в соответствии с их этическими и профессиональными обязательствами. Кроме того, медицинский работник обязан проверять действующие правила и положения, касающиеся лекарств и медицинских изделий, на момент назначения по рецепту.</p></abstract><trans-abstract xml:lang="en"><p>The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>острый коронарный синдром</kwd><kwd>инфаркт миокарда</kwd><kwd>инфаркт миокарда без подъемов сегмента ST</kwd><kwd>нестабильная стенокардия</kwd><kwd>чрескожное коронарное вмешательство</kwd></kwd-group><kwd-group xml:lang="en"><kwd>acute coronary syndrome</kwd><kwd>myocardial infarction</kwd><kwd>non-STsegment elevation myocardial infarction</kwd><kwd>percutaneous coronary intervention</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Salim Yusuf, Steven Hawken, Stephanie Ôunpuu, Tony Dans, Alvaro Avezum, Fernando Lanas, Matthew McQueen, Andrzej Budaj, Prem Pais, John Varigos, Liu Lisheng, on behalf of the INTERHEART Study InvestigatorsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–52.</mixed-citation><mixed-citation xml:lang="en">Salim Yusuf, Steven Hawken, Stephanie Ôunpuu, Tony Dans, Alvaro Avezum, Fernando Lanas, Matthew McQueen, Andrzej Budaj, Prem Pais, John Varigos, Liu Lisheng, on behalf of the INTERHEART Study InvestigatorsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–52.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics - 2015 Update. Circulation 2015;131:434–441.</mixed-citation><mixed-citation xml:lang="en">Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics - 2015 Update. Circulation 2015;131:434–441.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, Vollset SE, Ozgoren AA. , Abdalla S, Abd-Allah F, Abdel Aziz MI, Abera SF, Aboyans V, Abraham B, Abraham JP, Abuabara KE, Abubakar I, .Global, regional, and national age-sex specific all-cause and cause-cpecific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117–171.</mixed-citation><mixed-citation xml:lang="en">Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, Vollset SE, Ozgoren AA. , Abdalla S, Abd-Allah F, Abdel Aziz MI, Abera SF, Aboyans V, Abraham B, Abraham JP, Abuabara KE, Abubakar I, .Global, regional, and national age-sex specific all-cause and cause-cpecific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117–171.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Goldberg RJ, Currie K, White K, Brieger D, Steg PG, Goodman SG, Dabbous O, Fox KA, Gore JM. Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol. 2004 Feb 1;93(3):288-93. https://doi.org/10.1016/j.amjcard.2003.10.006, PMID: 14759376.</mixed-citation><mixed-citation xml:lang="en">Goldberg RJ, Currie K, White K, Brieger D, Steg PG, Goodman SG, Dabbous O, Fox KA, Gore JM. Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol. 2004 Feb 1;93(3):288-93. https://doi.org/10.1016/j.amjcard.2003.10.006, PMID: 14759376.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">А. Д . Эрилих и др. Шестимесячные исходы у пациентов с острым коронарным синдромом, включённых в российский регистр РЕКОРД-3. Российский кардиологический журнал 2017, 11 (151): 8–14</mixed-citation><mixed-citation xml:lang="en">А. Д . Эрилих и др. Шестимесячные исходы у пациентов с острым коронарным синдромом, включённых в российский регистр РЕКОРД-3. Российский кардиологический журнал 2017, 11 (151): 8–14</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sugiyama T, Hasegawa K, Kobayashi Y, Takahashi O, Fukui T, Tsugawa Y. Differential time trends of outcomes and costs of care for acute myocardial infarction hospitalizations by ST elevation and type of intervention in the United States, 2001-2011. J Am Heart Assoc 2015;4(3):e001445.</mixed-citation><mixed-citation xml:lang="en">Sugiyama T, Hasegawa K, Kobayashi Y, Takahashi O, Fukui T, Tsugawa Y. Differential time trends of outcomes and costs of care for acute myocardial infarction hospitalizations by ST elevation and type of intervention in the United States, 2001-2011. J Am Heart Assoc 2015;4(3):e001445.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, Goldberg RJ. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med 2011;124(1):40–47.</mixed-citation><mixed-citation xml:lang="en">McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, Goldberg RJ. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med 2011;124(1):40–47.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Khera S, Kolte D, Aronow WS, Palaniswamy C, Subramanian KS, Hashim T, Mujib M, Jain D, Paudel R, Ahmed A, Frishman WH, Bhatt DL, Panza JA, Fonarow GC. Non-ST-elevation myocardial infarction in the United States: contemporary trends in incidence, utilization of the early invasive strategy, and in-hospital outcomes. J Am Heart Assoc. 2014 Jul 28;3(4):e000995. https://doi.org/10.1161/JAHA.114.000995, PMID: 25074695; PMCID: PMC4310389.</mixed-citation><mixed-citation xml:lang="en">Khera S, Kolte D, Aronow WS, Palaniswamy C, Subramanian KS, Hashim T, Mujib M, Jain D, Paudel R, Ahmed A, Frishman WH, Bhatt DL, Panza JA, Fonarow GC. Non-ST-elevation myocardial infarction in the United States: contemporary trends in incidence, utilization of the early invasive strategy, and in-hospital outcomes. J Am Heart Assoc. 2014 Jul 28;3(4):e000995. https://doi.org/10.1161/JAHA.114.000995, PMID: 25074695; PMCID: PMC4310389.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Szummer K, Wallentin L, Lindhagen L, Alfredsson J, Erlinge D, Held C, James S, Kellerth T, Lindahl B, Ravn-Fischer A, Rydberg E, Yndigegn T, Jernberg T. Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. Eur Heart J. 2018 Nov 7;39(42):3766-3776. https://doi.org/10.1093/eurheartj/ehy554, PMID: 30239671.</mixed-citation><mixed-citation xml:lang="en">Szummer K, Wallentin L, Lindhagen L, Alfredsson J, Erlinge D, Held C, James S, Kellerth T, Lindahl B, Ravn-Fischer A, Rydberg E, Yndigegn T, Jernberg T. Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. Eur Heart J. 2018 Nov 7;39(42):3766-3776. https://doi.org/10.1093/eurheartj/ehy554, PMID: 30239671.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Puymirat E, Simon T, Cayla G, Cottin Y, Elbaz M, Coste P, Lemesle G, Motreff P, Popovic B, Khalife K, Labeque JN, Perret T, Le Ray C, Orion L, Jouve B, Blanchard D, Peycher P, Silvain J, Steg PG, Goldstein P, Gueret P, Belle L, . Aissaoui N, Ferrieres J, Schiele F, Danchin N, USIK, USIC 2000, and FAST-MI investigators. Acute myocardial infarction: changes in patient characteristics, management, and 6-month outcomes over a period of 20 years in the FASTMI program (French Registry of Acute ST-Elevation or Non-ST-Elevation. Myocardial Infarction) 1995 to 2015. Circulation 2017;136:1908-1919</mixed-citation><mixed-citation xml:lang="en">Puymirat E, Simon T, Cayla G, Cottin Y, Elbaz M, Coste P, Lemesle G, Motreff P, Popovic B, Khalife K, Labeque JN, Perret T, Le Ray C, Orion L, Jouve B, Blanchard D, Peycher P, Silvain J, Steg PG, Goldstein P, Gueret P, Belle L, . Aissaoui N, Ferrieres J, Schiele F, Danchin N, USIK, USIC 2000, and FAST-MI investigators. Acute myocardial infarction: changes in patient characteristics, management, and 6-month outcomes over a period of 20 years in the FASTMI program (French Registry of Acute ST-Elevation or Non-ST-Elevation. Myocardial Infarction) 1995 to 2015. Circulation 2017;136:1908-1919</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Henrikson CA, Howell EE, Bush DE, Miles JS, Meininger GR, Friedlander T, Bushnell AC, Chandra-Strobos N. Chest pain relief by nitroglycerin does not predict active coronary artery disease. Ann Intern Med 2003;139(12):979–986.</mixed-citation><mixed-citation xml:lang="en">Henrikson CA, Howell EE, Bush DE, Miles JS, Meininger GR, Friedlander T, Bushnell AC, Chandra-Strobos N. Chest pain relief by nitroglycerin does not predict active coronary artery disease. Ann Intern Med 2003;139(12):979–986.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Holmvang L, Clemmensen P, Lindahl B, Lagerqvist B, Venge P, Wagner G, . Wallentin L, Grande P. Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment. J Am Coll Cardiol 2003;41:905-915.</mixed-citation><mixed-citation xml:lang="en">Holmvang L, Clemmensen P, Lindahl B, Lagerqvist B, Venge P, Wagner G, . Wallentin L, Grande P. Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment. J Am Coll Cardiol 2003;41:905-915.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kaul P, Fu Y, Chang WC, Harrington RA, Wagner GS, Goodman SG, Granger CB, . Moliterno DJ, Van de Werf F, Califf RM, Topol EJ, Armstrong PW, PARAGON-A and . GUSTO-IIb Investigators. Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A . and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. J Am Coll Cardiol 2001;38:64-71</mixed-citation><mixed-citation xml:lang="en">Kaul P, Fu Y, Chang WC, Harrington RA, Wagner GS, Goodman SG, Granger CB, . Moliterno DJ, Van de Werf F, Califf RM, Topol EJ, Armstrong PW, PARAGON-A and . GUSTO-IIb Investigators. Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A . and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. J Am Coll Cardiol 2001;38:64-71</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Jacobsen MD, Wagner GS, Holmvang L, Kontny F, Wallentin L, Husted S, Swahn E, Stahle E, Steffensen R, Clemmensen P. Quantitative T-wave analysis predicts 1 year prognosis and benefit from early invasive treatment in the FRISC II study population. Eur Heart J 2005;26:112-118.</mixed-citation><mixed-citation xml:lang="en">Jacobsen MD, Wagner GS, Holmvang L, Kontny F, Wallentin L, Husted S, Swahn E, Stahle E, Steffensen R, Clemmensen P. Quantitative T-wave analysis predicts 1 year prognosis and benefit from early invasive treatment in the FRISC II study population. Eur Heart J 2005;26:112-118.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Yamaji H, Iwasaki K, Kusachi S, Murakami T, Hirami R, Hamamoto H, Hina K, Kita T, Sakakibara N, Tsuji T. Prediction of acute left main coronary artery obstruction by 12-lead electrocardiography. ST segment elevation in lead aVR with less ST segment elevation in lead V(1). J Am Coll Cardiol 2001;38:1348-1354.</mixed-citation><mixed-citation xml:lang="en">Yamaji H, Iwasaki K, Kusachi S, Murakami T, Hirami R, Hamamoto H, Hina K, Kita T, Sakakibara N, Tsuji T. Prediction of acute left main coronary artery obstruction by 12-lead electrocardiography. ST segment elevation in lead aVR with less ST segment elevation in lead V(1). J Am Coll Cardiol 2001;38:1348-1354.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Yan AT, Yan RT, Kennelly BM, Anderson FA, Jr., Budaj A, Lopez-Sendon J, Brieger D, Allegrone J, Steg G, Goodman SG, GRACE Investigators. Relationship of ST elevation in lead aVR with angiographic findings and outcome in non-ST elevation acute coronary syndromes. Am Heart J 2007;154:71-78</mixed-citation><mixed-citation xml:lang="en">Yan AT, Yan RT, Kennelly BM, Anderson FA, Jr., Budaj A, Lopez-Sendon J, Brieger D, Allegrone J, Steg G, Goodman SG, GRACE Investigators. Relationship of ST elevation in lead aVR with angiographic findings and outcome in non-ST elevation acute coronary syndromes. Am Heart J 2007;154:71-78</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">de Winter RJ, Verouden NJ, Wellens HJ, Wilde AA, Interventional Cardiology Group of the Academic Medical Center. A new ECG sign of proximal LAD occlusion. N Engl J Med 2008;359:2071-2073</mixed-citation><mixed-citation xml:lang="en">de Winter RJ, Verouden NJ, Wellens HJ, Wilde AA, Interventional Cardiology Group of the Academic Medical Center. A new ECG sign of proximal LAD occlusion. N Engl J Med 2008;359:2071-2073</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">de Zwaan C, Bar FW, Janssen JH, Cheriex EC, Dassen WR, Brugada P, Penn OC, Wellens HJ. Angiographic and clinical characteristics of patients with unstable angina showing an ECG pattern indicating critical narrowing of the proximal LAD coronary artery. Am Heart J 1989;117:657-665.</mixed-citation><mixed-citation xml:lang="en">de Zwaan C, Bar FW, Janssen JH, Cheriex EC, Dassen WR, Brugada P, Penn OC, Wellens HJ. Angiographic and clinical characteristics of patients with unstable angina showing an ECG pattern indicating critical narrowing of the proximal LAD coronary artery. Am Heart J 1989;117:657-665.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Matthew D Alvin, Allan S Jaffe, Roy C Ziegelstein, Jeffrey C Trost. Eliminating Creatine Kinase-Myocardial Band Testing in Suspected Acute Coronary Syndrome: A Value-Based Quality Improvement. A Intern Med. 2017 Oct 1;177(10):1508-1512.</mixed-citation><mixed-citation xml:lang="en">Matthew D Alvin, Allan S Jaffe, Roy C Ziegelstein, Jeffrey C Trost. Eliminating Creatine Kinase-Myocardial Band Testing in Suspected Acute Coronary Syndrome: A Value-Based Quality Improvement. A Intern Med. 2017 Oct 1;177(10):1508-1512.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Wildi K, Nelles B, Twerenbold R, Rubini Gimenez M, Reichlin T, Singeisen H, Druey S, Haaf P, Sabti Z, Hillinger P, Jaeger C, Campodarve I, Kreutzinger P, Puelacher C, Moreno Weidmann Z, Gugala M, Pretre G, Doerflinger S, Wagener M, Stallone F, Freese M, Stelzig C, Rentsch K, Bassetti S, Bingisser R, Osswald S, Mueller C. Safety and efficacy of the 0 h/3 h protocol for rapid rule out of myocardial infarction. Am Heart J 2016; 181: 16-25</mixed-citation><mixed-citation xml:lang="en">Wildi K, Nelles B, Twerenbold R, Rubini Gimenez M, Reichlin T, Singeisen H, Druey S, Haaf P, Sabti Z, Hillinger P, Jaeger C, Campodarve I, Kreutzinger P, Puelacher C, Moreno Weidmann Z, Gugala M, Pretre G, Doerflinger S, Wagener M, Stallone F, Freese M, Stelzig C, Rentsch K, Bassetti S, Bingisser R, Osswald S, Mueller C. Safety and efficacy of the 0 h/3 h protocol for rapid rule out of myocardial infarction. Am Heart J 2016; 181: 16-25</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Mueller C, Giannitsis E, Christ M, Ordonez-Llanos J, deFilippi C, McCord J, Body R, Panteghini M, Jernberg T, Plebani M, Verschuren F, French J, Christenson R, Weiser S, Bendig G, Dilba P, Lindahl B, Investigators T-A. Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T. Ann Emerg Med 2016; 68: 76-87</mixed-citation><mixed-citation xml:lang="en">Mueller C, Giannitsis E, Christ M, Ordonez-Llanos J, deFilippi C, McCord J, Body R, Panteghini M, Jernberg T, Plebani M, Verschuren F, French J, Christenson R, Weiser S, Bendig G, Dilba P, Lindahl B, Investigators T-A. Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T. Ann Emerg Med 2016; 68: 76-87</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Wildi K, Cullen L, Twerenbold R, Greenslade JH, Parsonage W, Boeddinghaus J, Nestelberger T, Sabti Z, Rubini-Gimenez M, Puelacher C, Cupa J, Schumacher L, Badertscher P, Grimm K, Kozhuharov N, Stelzig C, Freese M, Rentsch K, Lohrmann J, Kloos W, Buser A, Reichlin T, Pickering JW, Than M, Mueller C. Direct Comparison of 2 Rule-Out Strategies for Acute Myocardial Infarction: 2-h Accelerated Diagnostic Protocol vs 2-h Algorithm. Clin Chem 2017; 63: 1227-1236.</mixed-citation><mixed-citation xml:lang="en">Wildi K, Cullen L, Twerenbold R, Greenslade JH, Parsonage W, Boeddinghaus J, Nestelberger T, Sabti Z, Rubini-Gimenez M, Puelacher C, Cupa J, Schumacher L, Badertscher P, Grimm K, Kozhuharov N, Stelzig C, Freese M, Rentsch K, Lohrmann J, Kloos W, Buser A, Reichlin T, Pickering JW, Than M, Mueller C. Direct Comparison of 2 Rule-Out Strategies for Acute Myocardial Infarction: 2-h Accelerated Diagnostic Protocol vs 2-h Algorithm. Clin Chem 2017; 63: 1227-1236.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Boeddinghaus J, Twerenbold R, Nestelberger T, Badertscher P, Wildi K, Puelacher C, du Fay de Lavallaz J, Keser E, Rubini Gimenez M, Wussler D, Kozhuharov N, Rentsch K, Miro O, Martin- Sanchez FJ, Morawiec B, Stefanelli S, Geigy N, Keller DI, Reichlin T, Mueller C, Investigators A. Clinical Validation of a Novel High-Sensitivity Cardiac Troponin I Assay for Early Diagnosis of Acute Myocardial Infarction. Clin Chem 2018; 64: 1347-1360</mixed-citation><mixed-citation xml:lang="en">Boeddinghaus J, Twerenbold R, Nestelberger T, Badertscher P, Wildi K, Puelacher C, du Fay de Lavallaz J, Keser E, Rubini Gimenez M, Wussler D, Kozhuharov N, Rentsch K, Miro O, Martin- Sanchez FJ, Morawiec B, Stefanelli S, Geigy N, Keller DI, Reichlin T, Mueller C, Investigators A. Clinical Validation of a Novel High-Sensitivity Cardiac Troponin I Assay for Early Diagnosis of Acute Myocardial Infarction. Clin Chem 2018; 64: 1347-1360</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Badertscher P, Boeddinghaus J, Twerenbold R, Nestelberger T, Wildi K, Wussler D, Schwarz J, Puelacher C, Giménez MR, Kozhuharov N, de Lavallaz JF, Cerminara SE, Potlukova E, Rentsch K, Miró Ò, López B, MartinSanchez FJ, Morawiec B, Muzyk P, Keller DI., Reichlin T, Mueller C; for the APACE Investigators. Direct Comparison of the 0/1h and 0/3h Algorithms for Early Rule-Out of Acute Myocardial Infarction. Circulation 2018; 137: 2536-2538</mixed-citation><mixed-citation xml:lang="en">Badertscher P, Boeddinghaus J, Twerenbold R, Nestelberger T, Wildi K, Wussler D, Schwarz J, Puelacher C, Giménez MR, Kozhuharov N, de Lavallaz JF, Cerminara SE, Potlukova E, Rentsch K, Miró Ò, López B, MartinSanchez FJ, Morawiec B, Muzyk P, Keller DI., Reichlin T, Mueller C; for the APACE Investigators. Direct Comparison of the 0/1h and 0/3h Algorithms for Early Rule-Out of Acute Myocardial Infarction. Circulation 2018; 137: 2536-2538</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Fox K, Achenbach S, Bax J, Cosyns B, Delgado V, Dweck MR, Edvardsen T, . Flachskampf F, Habib G, Lancellotti P, Muraru D, Neglia D, Pontone G, . Schwammenthal E, Sechtem U, Westwood M, Popescu BA. Multimodality imag- . ing in cardiology: a statement on behalf of the Task Force on Multimodality . Imaging of the E</mixed-citation><mixed-citation xml:lang="en">Fox K, Achenbach S, Bax J, Cosyns B, Delgado V, Dweck MR, Edvardsen T, . Flachskampf F, Habib G, Lancellotti P, Muraru D, Neglia D, Pontone G, . Schwammenthal E, Sechtem U, Westwood M, Popescu BA. Multimodality imag- . ing in cardiology: a statement on behalf of the Task Force on Multimodality . Imaging of the E</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, . Poldermans D, Voigt JU, Zamorano JL, European Association of Echocardiography. Stress Echocardiography Expert Consensus . Statement Executive Summary: European Association of Echocardiography . (EAE) (a registered branch of the ESC). Eur Heart J 2009;30:278-289</mixed-citation><mixed-citation xml:lang="en">Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, . Poldermans D, Voigt JU, Zamorano JL, European Association of Echocardiography. Stress Echocardiography Expert Consensus . Statement Executive Summary: European Association of Echocardiography . (EAE) (a registered branch of the ESC). Eur Heart J 2009;30:278-289</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Senior R, Becher H, Monaghan M, Agati L, Zamorano J, Vanoverschelde JL, . Nihoyannopoulos P, Edvardsen T, Lancellotti P, EACVI Scientific Documents . Committee for 2014-16 and 2016-18, EACVI Scientific Documents Committee for 2014-16 and 2016, 18. Clinical practice of contrast echocardiography: recommendation by the European Association of Cardiovascular. Imaging (EACVI) 2017. Eur Heart J Cardiovasc Imaging 2017;18:1205-1205</mixed-citation><mixed-citation xml:lang="en">Senior R, Becher H, Monaghan M, Agati L, Zamorano J, Vanoverschelde JL, . Nihoyannopoulos P, Edvardsen T, Lancellotti P, EACVI Scientific Documents . Committee for 2014-16 and 2016-18, EACVI Scientific Documents Committee for 2014-16 and 2016, 18. Clinical practice of contrast echocardiography: recommendation by the European Association of Cardiovascular. Imaging (EACVI) 2017. Eur Heart J Cardiovasc Imaging 2017;18:1205-1205</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Lim SH, Anantharaman V, Sundram F, Chan ES, Ang ES, Yo SL, Jacob E, Goh A, Tan SB, Chua T. Stress myocardial perfusion imaging for the evaluation and tri- age of chest pain in the emergency department: a randomized controlled trial. J Nucl Cardiol 2013;20:1002-1012</mixed-citation><mixed-citation xml:lang="en">Lim SH, Anantharaman V, Sundram F, Chan ES, Ang ES, Yo SL, Jacob E, Goh A, Tan SB, Chua T. Stress myocardial perfusion imaging for the evaluation and tri- age of chest pain in the emergency department: a randomized controlled trial. J Nucl Cardiol 2013;20:1002-1012</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ingkanisorn WP, Kwong RY, Bohme NS, Geller NL, Rhoads KL, Dyke CK, Paterson DI, Syed MA, Aletras AH, Arai AE. Prognosis of negative adenosine stress magnetic resonance in patients presenting to an emergency department . with chest pain. J Am Coll Cardiol 2006;47:1427-1432.</mixed-citation><mixed-citation xml:lang="en">Ingkanisorn WP, Kwong RY, Bohme NS, Geller NL, Rhoads KL, Dyke CK, Paterson DI, Syed MA, Aletras AH, Arai AE. Prognosis of negative adenosine stress magnetic resonance in patients presenting to an emergency department . with chest pain. J Am Coll Cardiol 2006;47:1427-1432.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Goldstein JA, Gallagher MJ, O»Neill WW, Ross MA, O»Neil BJ, Raff GL. A randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain. J Am Coll Cardiol 2007; 49: 863-871</mixed-citation><mixed-citation xml:lang="en">Goldstein JA, Gallagher MJ, O»Neill WW, Ross MA, O»Neil BJ, Raff GL. A randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain. J Am Coll Cardiol 2007; 49: 863-871</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Samad Z, Hakeem A, Mahmood SS, Pieper K, Patel MR, Simel DL, Douglas PS. A meta-analysis and systematic review of computed tomography angiography as a diagnostic triage tool for patients with chest pain presenting to the emergency department. J Nucl Cardiol 2012; 19: 364- 376</mixed-citation><mixed-citation xml:lang="en">Samad Z, Hakeem A, Mahmood SS, Pieper K, Patel MR, Simel DL, Douglas PS. A meta-analysis and systematic review of computed tomography angiography as a diagnostic triage tool for patients with chest pain presenting to the emergency department. J Nucl Cardiol 2012; 19: 364- 376</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Goldstein JA, Chinnaiyan KM, Abidov A, et al. The CT-STAT (Coronary Computed Tomographic Hoffmann U, Bamberg F, Chae CU, et al. Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. J Am Coll Cardiol. 2009; 53: 1642-1650</mixed-citation><mixed-citation xml:lang="en">Goldstein JA, Chinnaiyan KM, Abidov A, et al. The CT-STAT (Coronary Computed Tomographic Hoffmann U, Bamberg F, Chae CU, et al. Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. J Am Coll Cardiol. 2009; 53: 1642-1650</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Rubini Gimenez M, Twerenbold R, Reichlin T, Wildi K, Haaf P, Schaefer M, Zellweger C, Moehring B, Stallone F, Sou SM, Mueller M, Denhaerynck K, Mosimann T, Reiter M, Meller B, Freese M, Stelzig C, Klimmeck I, Voegele J, Hartmann B, Rentsch K, Osswald S, Mueller C. Direct comparison of highsensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction. Eur Heart J 2014;35:23032311.</mixed-citation><mixed-citation xml:lang="en">Rubini Gimenez M, Twerenbold R, Reichlin T, Wildi K, Haaf P, Schaefer M, Zellweger C, Moehring B, Stallone F, Sou SM, Mueller M, Denhaerynck K, Mosimann T, Reiter M, Meller B, Freese M, Stelzig C, Klimmeck I, Voegele J, Hartmann B, Rentsch K, Osswald S, Mueller C. Direct comparison of highsensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction. Eur Heart J 2014;35:23032311.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Haaf P, Reichlin T, Twerenbold R, Hoeller R, Rubini Gimenez M, Zellweger C, Moehring B, Fischer C, Meller B, Wildi K, Freese M, Stelzig C, Mosimann T, Reiter M, Mueller M, Hochgruber T, Sou SM, Murray K, Minners J, Freidank H, Osswald S, Mueller C. Risk stratification in patients with acute chest pain using three high-sensitivity cardiac troponin assays. Eur Heart J 2014;35:365375.</mixed-citation><mixed-citation xml:lang="en">Haaf P, Reichlin T, Twerenbold R, Hoeller R, Rubini Gimenez M, Zellweger C, Moehring B, Fischer C, Meller B, Wildi K, Freese M, Stelzig C, Mosimann T, Reiter M, Mueller M, Hochgruber T, Sou SM, Murray K, Minners J, Freidank H, Osswald S, Mueller C. Risk stratification in patients with acute chest pain using three high-sensitivity cardiac troponin assays. Eur Heart J 2014;35:365375.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Mueller C. Biomarkers and acute coronary syndromes: an update. Eur Heart J 2014;35:552556.</mixed-citation><mixed-citation xml:lang="en">Mueller C. Biomarkers and acute coronary syndromes: an update. Eur Heart J 2014;35:552556.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Reichlin T, Schindler C, Drexler B, Twerenbold R, Reiter M, Zellweger C, Moehring B, Ziller R, Hoeller R, Rubini Gimenez M, Haaf P, Potocki M, Wildi K, Balmelli C, Freese M, Stelzig C, Freidank H, Osswald S, Mueller C. Onehour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Arch Intern Med 2012;172:12111218.</mixed-citation><mixed-citation xml:lang="en">Reichlin T, Schindler C, Drexler B, Twerenbold R, Reiter M, Zellweger C, Moehring B, Ziller R, Hoeller R, Rubini Gimenez M, Haaf P, Potocki M, Wildi K, Balmelli C, Freese M, Stelzig C, Freidank H, Osswald S, Mueller C. Onehour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Arch Intern Med 2012;172:12111218.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, Huber K, Plebani M, Biasucci LM, Tubaro M, Collinson P, Venge P, Hasin Y, Galvani M, Koenig W, Hamm C, Alpert JS, Katus H, Jaffe AS, Study Group on Biomarkers in Cardiology of ESC Working Group on Acute Cardiac Care. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012;33:22522257.</mixed-citation><mixed-citation xml:lang="en">Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, Huber K, Plebani M, Biasucci LM, Tubaro M, Collinson P, Venge P, Hasin Y, Galvani M, Koenig W, Hamm C, Alpert JS, Katus H, Jaffe AS, Study Group on Biomarkers in Cardiology of ESC Working Group on Acute Cardiac Care. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012;33:22522257.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, Hasin Y, Biasucci LM, Giannitsis E, Lindahl B, Koenig W, Tubaro M, Collinson P, Katus H, Galvani M, Venge P, Alpert JS, Hamm C, Jaffe AS, Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J 2012;33:20012006.</mixed-citation><mixed-citation xml:lang="en">Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, Hasin Y, Biasucci LM, Giannitsis E, Lindahl B, Koenig W, Tubaro M, Collinson P, Katus H, Galvani M, Venge P, Alpert JS, Hamm C, Jaffe AS, Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J 2012;33:20012006.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:10141021.</mixed-citation><mixed-citation xml:lang="en">de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:10141021.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald E. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-STelevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003;41:12641272.</mixed-citation><mixed-citation xml:lang="en">Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald E. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-STelevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003;41:12641272.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, Avezum A, Goodman SG, Flather MD, Anderson FA, Jr., Granger CB. Prediction of risk of death and myocardial infarction in the six months after pre- sentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006;333:1091.</mixed-citation><mixed-citation xml:lang="en">Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, Avezum A, Goodman SG, Flather MD, Anderson FA, Jr., Granger CB. Prediction of risk of death and myocardial infarction in the six months after pre- sentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006;333:1091.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Fox KA, Eagle KA, Gore JM, Steg PG, Anderson FA, GRACE and GRACE2 Investigators. The Global Registry of Acute Coronary Events, 1999 to 2009􏰅GRACE. Heart 2010;96:1095-1101.</mixed-citation><mixed-citation xml:lang="en">Fox KA, Eagle KA, Gore JM, Steg PG, Anderson FA, GRACE and GRACE2 Investigators. The Global Registry of Acute Coronary Events, 1999 to 2009􏰅GRACE. Heart 2010;96:1095-1101.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset . T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, . James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, . Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, . Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. . Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research for . High Bleeding Risk. Eur Heart J 2019;40:2632-2653.</mixed-citation><mixed-citation xml:lang="en">Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset . T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, . James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, . Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, . Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. . Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research for . High Bleeding Risk. Eur Heart J 2019;40:2632-2653.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Davide Cao, Roxana Mehran, George Dangas, Usman Baber, Samantha Sartori, Rishi Chandiramani, Giulio G Stefanini, Dominick J Angiolillo, Davide Capodanno, Philip Urban, Marie-Claude Morice, Mitchell Krucoff, Ridhima Goel, Anastasios Roumeliotis, Joseph Sweeny, Samin K Sharma, Annapoorna Kini. Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. Coll Cardiol. 2020 Jun 2;75(21):2711-2722.</mixed-citation><mixed-citation xml:lang="en">Davide Cao, Roxana Mehran, George Dangas, Usman Baber, Samantha Sartori, Rishi Chandiramani, Giulio G Stefanini, Dominick J Angiolillo, Davide Capodanno, Philip Urban, Marie-Claude Morice, Mitchell Krucoff, Ridhima Goel, Anastasios Roumeliotis, Joseph Sweeny, Samin K Sharma, Annapoorna Kini. Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. Coll Cardiol. 2020 Jun 2;75(21):2711-2722.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019; 40: 237-269.</mixed-citation><mixed-citation xml:lang="en">Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019; 40: 237-269.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020 Aug 29:ehaa575. https://doi.org/10.1093/eurheartj/ehaa575, Epub ahead of print. PMID: 32860058.</mixed-citation><mixed-citation xml:lang="en">Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020 Aug 29:ehaa575. https://doi.org/10.1093/eurheartj/ehaa575, Epub ahead of print. PMID: 32860058.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Kolte D, Khera S, Dabhadkar KC, Agarwal S, Aronow WS, Timmermans R, Jain D, Cooper HA, Frishman WH, Menon V, Bhatt DL, Abbott JD, Fonarow GC, Panza JA. Trends in coronary angiography, revascularization, and outcomes of cardiogenic shock complicating non-ST-elevation myocardial infarction. Am J Cardiol 2016; 117: 1-9.</mixed-citation><mixed-citation xml:lang="en">Kolte D, Khera S, Dabhadkar KC, Agarwal S, Aronow WS, Timmermans R, Jain D, Cooper HA, Frishman WH, Menon V, Bhatt DL, Abbott JD, Fonarow GC, Panza JA. Trends in coronary angiography, revascularization, and outcomes of cardiogenic shock complicating non-ST-elevation myocardial infarction. Am J Cardiol 2016; 117: 1-9.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, Afzal R, Chrolavicius S, Jolly SS, Widimsky P, Avezum A, Rupprecht HJ, Zhu J, Col J, Natarajan MK, Horsman C, Fox KA, Yusuf S; TIMACS Investigators. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009; 360: 2165-2175.</mixed-citation><mixed-citation xml:lang="en">Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, Afzal R, Chrolavicius S, Jolly SS, Widimsky P, Avezum A, Rupprecht HJ, Zhu J, Col J, Natarajan MK, Horsman C, Fox KA, Yusuf S; TIMACS Investigators. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009; 360: 2165-2175.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Katritsis DG, Siontis GC, Kastrati A, van’t Hof AW, Neumann FJ, Siontis KC, . Ioannidis JP. Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. Eur Heart J 2011; 32: 32-40.</mixed-citation><mixed-citation xml:lang="en">Katritsis DG, Siontis GC, Kastrati A, van’t Hof AW, Neumann FJ, Siontis KC, . Ioannidis JP. Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. Eur Heart J 2011; 32: 32-40.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Navarese EP, Gurbel PA, Andreotti F, Tantry U, Jeong YH, Kozinski M, Engstrom T, Di Pasquale G, Kochman W, Ardissino D, Kedhi E, Stone GW, Kubica J. Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. Ann Intern Med 2013; 158: 261-70.</mixed-citation><mixed-citation xml:lang="en">Navarese EP, Gurbel PA, Andreotti F, Tantry U, Jeong YH, Kozinski M, Engstrom T, Di Pasquale G, Kochman W, Ardissino D, Kedhi E, Stone GW, Kubica J. Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. Ann Intern Med 2013; 158: 261-70.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Milasinovic D, Milosevic A, Marinkovic J, Vukcevic V, Ristic A, Asanin M, Stankovic G. Timing of invasive strategy in NSTE-ACS patients and effect on clinical outcomes: A systematic review and meta-analysis of randomized controlled trials. Atherosclerosis 2015; 241: 48-54.</mixed-citation><mixed-citation xml:lang="en">Milasinovic D, Milosevic A, Marinkovic J, Vukcevic V, Ristic A, Asanin M, Stankovic G. Timing of invasive strategy in NSTE-ACS patients and effect on clinical outcomes: A systematic review and meta-analysis of randomized controlled trials. Atherosclerosis 2015; 241: 48-54.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Bonello L, Laine M, Puymirat E, Lemesle G, Thuny F, Paganelli F, Michelet P, Roch A, Kerbaul F, Boyer L. Timing of Coronary Invasive Strategy in NonST-Segment Elevation Acute Coronary Syndromes and Clinical Outcomes: An Updated Meta-Analysis. JACC Cardiovasc Interv 2016; 9: 2267-2276.</mixed-citation><mixed-citation xml:lang="en">Bonello L, Laine M, Puymirat E, Lemesle G, Thuny F, Paganelli F, Michelet P, Roch A, Kerbaul F, Boyer L. Timing of Coronary Invasive Strategy in NonST-Segment Elevation Acute Coronary Syndromes and Clinical Outcomes: An Updated Meta-Analysis. JACC Cardiovasc Interv 2016; 9: 2267-2276.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Jobs A, Mehta SR, Montalescot G, Vicaut E, Van’t Hof AWJ, Badings EA, Neumann FJ, Kastrati A, Sciahbasi A, Reuter PG, Lapostolle F, Milosevic A, Stankovic G, Milasinovic D, Vonthein R, Desch S, Thiele H. Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: A meta-analysis of randomised trials. Lancet 2017; 390: 737-746.</mixed-citation><mixed-citation xml:lang="en">Jobs A, Mehta SR, Montalescot G, Vicaut E, Van’t Hof AWJ, Badings EA, Neumann FJ, Kastrati A, Sciahbasi A, Reuter PG, Lapostolle F, Milosevic A, Stankovic G, Milasinovic D, Vonthein R, Desch S, Thiele H. Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: A meta-analysis of randomised trials. Lancet 2017; 390: 737-746.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Kofoed KF, Kelbaek H, Hansen PR, Torp-Pedersen C, Hofsten D, Klovgaard L, Holmvang L, Helqvist S, Jorgensen E, Galatius S, Pedersen F, Bang L, Saunamaki K, Clemmensen P, Linde JJ, Heitmann M, Wendelboe Nielsen O, Raymond IE, Kristiansen OP, Svendsen IH, Bech J, Dominguez Vall-Lamora MH, Kragelund C, Hansen TF, Dahlgaard Hove J, Jorgensen T, Fornitz GG, Steffensen R, Jurlander B, Abdulla J, Lyngbaek S, Elming H, Therkelsen SK, Abildgaard U, Jensen JS, Gislason G, Kober LV, Engstrom T. Early Versus Standard Care Invasive Examination and Treatment of Patients With NonST-Segment Elevation Acute Coronary Syndrome. Circulation 2018; 138: 2741-2750.</mixed-citation><mixed-citation xml:lang="en">Kofoed KF, Kelbaek H, Hansen PR, Torp-Pedersen C, Hofsten D, Klovgaard L, Holmvang L, Helqvist S, Jorgensen E, Galatius S, Pedersen F, Bang L, Saunamaki K, Clemmensen P, Linde JJ, Heitmann M, Wendelboe Nielsen O, Raymond IE, Kristiansen OP, Svendsen IH, Bech J, Dominguez Vall-Lamora MH, Kragelund C, Hansen TF, Dahlgaard Hove J, Jorgensen T, Fornitz GG, Steffensen R, Jurlander B, Abdulla J, Lyngbaek S, Elming H, Therkelsen SK, Abildgaard U, Jensen JS, Gislason G, Kober LV, Engstrom T. Early Versus Standard Care Invasive Examination and Treatment of Patients With NonST-Segment Elevation Acute Coronary Syndrome. Circulation 2018; 138: 2741-2750.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: A meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006; 48: 1319-1325.</mixed-citation><mixed-citation xml:lang="en">Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: A meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006; 48: 1319-1325.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JG, Lagerqvist B, Wallentin L, FIR Collaboration. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol 2010; 55: 2435-2445.</mixed-citation><mixed-citation xml:lang="en">Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JG, Lagerqvist B, Wallentin L, FIR Collaboration. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol 2010; 55: 2435-2445.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Nyman I, Wallentin L, Areskog M, Areskog NH, Swahn E. Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC study group. Int J Cardiol 1993; 39: 131-142.</mixed-citation><mixed-citation xml:lang="en">Nyman I, Wallentin L, Areskog M, Areskog NH, Swahn E. Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC study group. Int J Cardiol 1993; 39: 131-142.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Amsterdam EA, Kirk JD, Diercks DB, Lewis WR, Turnipseed SD. Immediate exercise testing to evaluate low-risk patients presenting to the emergency department with chest pain. J Am Coll Cardiol 2002; 40: 251-256.</mixed-citation><mixed-citation xml:lang="en">Amsterdam EA, Kirk JD, Diercks DB, Lewis WR, Turnipseed SD. Immediate exercise testing to evaluate low-risk patients presenting to the emergency department with chest pain. J Am Coll Cardiol 2002; 40: 251-256.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Siontis GC, Mavridis D, Greenwood JP, Coles B, Nikolakopoulou A, Juni P, Salanti G, Windecker S. Outcomes of non-invasive diagnostic modalities for the detection of coronary artery disease: network meta-analysis of diagnostic randomised controlled trials. BMJ 2018; 360: k504.</mixed-citation><mixed-citation xml:lang="en">Siontis GC, Mavridis D, Greenwood JP, Coles B, Nikolakopoulou A, Juni P, Salanti G, Windecker S. Outcomes of non-invasive diagnostic modalities for the detection of coronary artery disease: network meta-analysis of diagnostic randomised controlled trials. BMJ 2018; 360: k504.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87-165.</mixed-citation><mixed-citation xml:lang="en">Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87-165.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Ntalianis A, Sels JW, Davidavicius G, Tanaka N, Muller O, Trana C, Barbato E, Hamilos M, Mangiacapra F, Heyndrickx GR, Wijns W, Pijls NH, De Bruyne B. Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction. JACC Cardiovasc Interv 2010; 3: 1274-1281.</mixed-citation><mixed-citation xml:lang="en">Ntalianis A, Sels JW, Davidavicius G, Tanaka N, Muller O, Trana C, Barbato E, Hamilos M, Mangiacapra F, Heyndrickx GR, Wijns W, Pijls NH, De Bruyne B. Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction. JACC Cardiovasc Interv 2010; 3: 1274-1281.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Sardella G, Lucisano L, Garbo R, Pennacchi M, Cavallo E, Stio RE, Calcagno S, Ugo F, Boccuzzi G, Fedele F, Mancone M. Single-Staged Compared With Multi-Staged PCI in Multivessel NSTEMI Patients: The SMILE Trial. J Am Coll Cardiol 2016; 67: 264-272.</mixed-citation><mixed-citation xml:lang="en">Sardella G, Lucisano L, Garbo R, Pennacchi M, Cavallo E, Stio RE, Calcagno S, Ugo F, Boccuzzi G, Fedele F, Mancone M. Single-Staged Compared With Multi-Staged PCI in Multivessel NSTEMI Patients: The SMILE Trial. J Am Coll Cardiol 2016; 67: 264-272.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Chang M, Lee CW, Ahn JM, Cavalcante R, Sotomi Y, Onuma Y, Han M, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Serruys PW, Park SJ. Comparison of outcome of coronary artery bypass grafting versus drug-eluting stent implantation for non-ST-elevation acute coronary syndrome. Am J Cardiol 2017; 120: 380-386.</mixed-citation><mixed-citation xml:lang="en">Chang M, Lee CW, Ahn JM, Cavalcante R, Sotomi Y, Onuma Y, Han M, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Serruys PW, Park SJ. Comparison of outcome of coronary artery bypass grafting versus drug-eluting stent implantation for non-ST-elevation acute coronary syndrome. Am J Cardiol 2017; 120: 380-386.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Rathod KS, Koganti S, Jain AK, Astroulakis Z, Lim P, Rakhit R, Kalra SS, Dalby MC, O’Mahony C, Malik IS, Knight CJ, Mathur A, Redwood S, Sirker A, MacCarthy PA, Smith EJ, Wragg A, Jones DA. Complete versus culpritonly lesion intervention in patients with acute coronary syndromes. J Am Coll Cardiol 2018;72:1989_1999.</mixed-citation><mixed-citation xml:lang="en">Rathod KS, Koganti S, Jain AK, Astroulakis Z, Lim P, Rakhit R, Kalra SS, Dalby MC, O’Mahony C, Malik IS, Knight CJ, Mathur A, Redwood S, Sirker A, MacCarthy PA, Smith EJ, Wragg A, Jones DA. Complete versus culpritonly lesion intervention in patients with acute coronary syndromes. J Am Coll Cardiol 2018;72:1989_1999.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Nordmann AJ., Hengstler P., Leimenstoll BM., Harr T., Young J., C Bucher H. Clinical outcomes of stents versus balloon angioplasty in non-acute coronary artery disease: A meta-analysis of randomized controlled trials. Eur Heart J 2004; 25: 69–80.</mixed-citation><mixed-citation xml:lang="en">Nordmann AJ., Hengstler P., Leimenstoll BM., Harr T., Young J., C Bucher H. Clinical outcomes of stents versus balloon angioplasty in non-acute coronary artery disease: A meta-analysis of randomized controlled trials. Eur Heart J 2004; 25: 69–80.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Moses JW, Mehran R, Nikolsky E, Lasala JM, Corey W, Albin G, Hirsch C, Leon MB, Russell ME, Ellis SG, Stone GW. Outcomes with the paclitaxeleluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005; 45: 1165-1171.</mixed-citation><mixed-citation xml:lang="en">Moses JW, Mehran R, Nikolsky E, Lasala JM, Corey W, Albin G, Hirsch C, Leon MB, Russell ME, Ellis SG, Stone GW. Outcomes with the paclitaxeleluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005; 45: 1165-1171.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and efficacy of drugeluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198-3206.</mixed-citation><mixed-citation xml:lang="en">Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and efficacy of drugeluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198-3206.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B, Bertel O, Bonetti P, De Servi S, Brunner-La Rocca HP, Ricard I, Pfisterer M. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010; 363: 2310-2319.</mixed-citation><mixed-citation xml:lang="en">Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B, Bertel O, Bonetti P, De Servi S, Brunner-La Rocca HP, Ricard I, Pfisterer M. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010; 363: 2310-2319.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Greenhalgh J, Hockenhull J, Rao N, Dundar Y, Dickson RC, Bagust A. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev 2010; 5: CD004587.</mixed-citation><mixed-citation xml:lang="en">Greenhalgh J, Hockenhull J, Rao N, Dundar Y, Dickson RC, Bagust A. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev 2010; 5: CD004587.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Raber L, Kelbaek H, Ostojic M, Baumbach A, Heg D, Tuller D, von Birgelen C, Roffi M, Moschovitis A, Khattab AA, Wenaweser P, Bonvini R, Pedrazzini G, Kornowski R, Weber K, Trelle S, Luscher TF, Taniwaki M, Matter CM, Meier B, Juni P, Windecker S. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012; 308: 777-787.</mixed-citation><mixed-citation xml:lang="en">Raber L, Kelbaek H, Ostojic M, Baumbach A, Heg D, Tuller D, von Birgelen C, Roffi M, Moschovitis A, Khattab AA, Wenaweser P, Bonvini R, Pedrazzini G, Kornowski R, Weber K, Trelle S, Luscher TF, Taniwaki M, Matter CM, Meier B, Juni P, Windecker S. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012; 308: 777-787.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patientyears of follow-up from randomized trials. Circulation 2012; 125: 2873-2891.</mixed-citation><mixed-citation xml:lang="en">Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patientyears of follow-up from randomized trials. Circulation 2012; 125: 2873-2891.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, Faxon DP, Feit F. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ 2013; 347: f6625.</mixed-citation><mixed-citation xml:lang="en">Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, Faxon DP, Feit F. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ 2013; 347: f6625.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G. Two- year outcomes after first- or second-generation drug-eluting or baremetal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (prolonging dual antiplate- let treatment after grading stent-induced intimal hyperplasia study). JACC Cardiovasc Interv 2014; 7: 20–28.</mixed-citation><mixed-citation xml:lang="en">Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G. Two- year outcomes after first- or second-generation drug-eluting or baremetal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (prolonging dual antiplate- let treatment after grading stent-induced intimal hyperplasia study). JACC Cardiovasc Interv 2014; 7: 20–28.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Airoldi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P, BriguoriC; ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 2015; 65: 805-815.</mixed-citation><mixed-citation xml:lang="en">Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Airoldi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P, BriguoriC; ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 2015; 65: 805-815.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Urban P, Meredith IT, Abizaid A, et al.; LEADERS FREE Investigators. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. N Engl J Med 2015; 373: 2038-2047.</mixed-citation><mixed-citation xml:lang="en">Urban P, Meredith IT, Abizaid A, et al.; LEADERS FREE Investigators. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. N Engl J Med 2015; 373: 2038-2047.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Garot P, Morice MC, Tresukosol D3, et al.; LEADERS FREE Investigators. 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free DrugCoated Stents. J Am Coll Cardiol 2017; 69: 162-171.</mixed-citation><mixed-citation xml:lang="en">Garot P, Morice MC, Tresukosol D3, et al.; LEADERS FREE Investigators. 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free DrugCoated Stents. J Am Coll Cardiol 2017; 69: 162-171.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Valgimigli M, Gagnor A, Calabro P, Frigoli E, Leonardi S, Zaro T, Rubartelli P, Briguori C, Ando G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A, Galli M, Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F, Esposito G, Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N, Rigattieri S, Tosi P, Palmieri C, Brugaletta S, Rao SV, Heg D, Rothenbuhler M, Vranckx P, Juni P. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomized multicentre trial. Lancet 2015; 385: 2465-2476.</mixed-citation><mixed-citation xml:lang="en">Valgimigli M, Gagnor A, Calabro P, Frigoli E, Leonardi S, Zaro T, Rubartelli P, Briguori C, Ando G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A, Galli M, Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F, Esposito G, Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N, Rigattieri S, Tosi P, Palmieri C, Brugaletta S, Rao SV, Heg D, Rothenbuhler M, Vranckx P, Juni P. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomized multicentre trial. Lancet 2015; 385: 2465-2476.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Nardin M, Verdoia M, Barbieri L, Schaffer A, Suryapranata H, De Luca G Radial vs Femoral Approach in Acute Coronary Syndromes: A Meta-Analysis of Randomized Trials. Curr Vasc Pharmacol 2017; 16: 79-92.</mixed-citation><mixed-citation xml:lang="en">Nardin M, Verdoia M, Barbieri L, Schaffer A, Suryapranata H, De Luca G Radial vs Femoral Approach in Acute Coronary Syndromes: A Meta-Analysis of Randomized Trials. Curr Vasc Pharmacol 2017; 16: 79-92.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Ranasinghe I, Alprandi-Costa B, Chow V, Elliott JM, Waites J, Counsell JT, Lopez-Sendon J, Avezum A, Goodman SG, Granger CB, Brieger D. Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007. Am J Cardiol 2011; 108: 617-624.</mixed-citation><mixed-citation xml:lang="en">Ranasinghe I, Alprandi-Costa B, Chow V, Elliott JM, Waites J, Counsell JT, Lopez-Sendon J, Avezum A, Goodman SG, Granger CB, Brieger D. Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007. Am J Cardiol 2011; 108: 617-624.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Malm CJ, Hansson EC, Akesson J, Andersson M, Hesse C, Shams Hakimi C, Jeppsson A. Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients: A prospective observational study. Br J Anaesth 2016; 117: 309-315.</mixed-citation><mixed-citation xml:lang="en">Malm CJ, Hansson EC, Akesson J, Andersson M, Hesse C, Shams Hakimi C, Jeppsson A. Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients: A prospective observational study. Br J Anaesth 2016; 117: 309-315.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Fukui T, Tabata M, Morita S, Takanashi S. Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris. J Thorac Cardiovasc Surg 2013; 145: 1577–1583.</mixed-citation><mixed-citation xml:lang="en">Fukui T, Tabata M, Morita S, Takanashi S. Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris. J Thorac Cardiovasc Surg 2013; 145: 1577–1583.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Davierw ala PM., Verevkin A, Leontyev S, Misfeld M, Borger MA., Mohr FW. Does Timing of Coronary Artery Bypass Surgery Affect Early and LongTerm Outcomes in Patients With Non–ST-Segment–Elevation Myocardial Infarction? Circulation 2015; 132: 731-740.</mixed-citation><mixed-citation xml:lang="en">Davierw ala PM., Verevkin A, Leontyev S, Misfeld M, Borger MA., Mohr FW. Does Timing of Coronary Artery Bypass Surgery Affect Early and LongTerm Outcomes in Patients With Non–ST-Segment–Elevation Myocardial Infarction? Circulation 2015; 132: 731-740.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE 3rd, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration cooperative study. N Engl J Med 1983; 309: 396-403.</mixed-citation><mixed-citation xml:lang="en">Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE 3rd, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration cooperative study. N Engl J Med 1983; 309: 396-403.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Hansson EC, Jideus L, Aberg B, Bjursten H, Dreifaldt M, Holmgren A, Ivert T, Nozohoor S, Barbu M, Svedjeholm R, Jeppsson A. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: A nationwide study. Eur Heart J 2016; 37: 189-197.</mixed-citation><mixed-citation xml:lang="en">Hansson EC, Jideus L, Aberg B, Bjursten H, Dreifaldt M, Holmgren A, Ivert T, Nozohoor S, Barbu M, Svedjeholm R, Jeppsson A. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: A nationwide study. Eur Heart J 2016; 37: 189-197.</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Tomsic A, Schotborgh MA, Manshanden JS, Li WW, de Mol BA. Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment. Eur J Cardiothorac Surg 2016; 50: 849-856.</mixed-citation><mixed-citation xml:lang="en">Tomsic A, Schotborgh MA, Manshanden JS, Li WW, de Mol BA. Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment. Eur J Cardiothorac Surg 2016; 50: 849-856.</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Gherli R, Mariscalco G, Dalen M, Onorati F, Perrotti A, Chocron S, Verhoye JP, Gulbins H, Reichart D, Svenarud P, Faggian G, Santarpino G, Fischlein T, Maselli D, Dominici C, Musumeci F, Rubino AS, Mignosa C, De Feo M, Bancone C, Gatti G, Maschietto L, Santini F, Nicolini F, Gherli T, Zanobini M, Kinnunen EM, Ruggieri VG, Rosato S, Biancari F. Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting. JAMA Cardiol 2016; 1: 921-928.</mixed-citation><mixed-citation xml:lang="en">Gherli R, Mariscalco G, Dalen M, Onorati F, Perrotti A, Chocron S, Verhoye JP, Gulbins H, Reichart D, Svenarud P, Faggian G, Santarpino G, Fischlein T, Maselli D, Dominici C, Musumeci F, Rubino AS, Mignosa C, De Feo M, Bancone C, Gatti G, Maschietto L, Santini F, Nicolini F, Gherli T, Zanobini M, Kinnunen EM, Ruggieri VG, Rosato S, Biancari F. Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting. JAMA Cardiol 2016; 1: 921-928.</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Nijjer SS, Watson G, Athanasiou T, Malik IS. Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. Eur Heart J 2011; 32: 2970-2888.</mixed-citation><mixed-citation xml:lang="en">Nijjer SS, Watson G, Athanasiou T, Malik IS. Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. Eur Heart J 2011; 32: 2970-2888.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Held C, Åsenblad N, Bassand J-P, Becker RC., Cannon CP., Claeys MJ., Harrington RA., Horrow J, Husted S, James SK., Mahaffey KW., Nicolau JC., Scirica BM., Storey RF., Vintila M, Ycas J, Wallentin L. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. Results From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. J Am Coll Cardiol 2011 57: 672-684.</mixed-citation><mixed-citation xml:lang="en">Held C, Åsenblad N, Bassand J-P, Becker RC., Cannon CP., Claeys MJ., Harrington RA., Horrow J, Husted S, James SK., Mahaffey KW., Nicolau JC., Scirica BM., Storey RF., Vintila M, Ycas J, Wallentin L. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. Results From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. J Am Coll Cardiol 2011 57: 672-684.</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Smith PK., Goodnough LT., Levy JH., Poston RS., Short MA., Weerakkody GJ., LeNarz LA. Mortality Benefit With Prasugrel in the TRITON–TIMI 38 Coronary Artery Bypass Grafting Cohort. Risk-Adjusted Retrospective Data Analysis. J Am Coll Cardiol 2012; 60: 388-389.</mixed-citation><mixed-citation xml:lang="en">Smith PK., Goodnough LT., Levy JH., Poston RS., Short MA., Weerakkody GJ., LeNarz LA. Mortality Benefit With Prasugrel in the TRITON–TIMI 38 Coronary Artery Bypass Grafting Cohort. Risk-Adjusted Retrospective Data Analysis. J Am Coll Cardiol 2012; 60: 388-389.</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Hansson C, Rexius H, Dellborg M, Albertsson P, Jeppsson A. Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor. Eur J Cardio-Thoracic Surg 2014; 46: 699-705.</mixed-citation><mixed-citation xml:lang="en">Hansson C, Rexius H, Dellborg M, Albertsson P, Jeppsson A. Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor. Eur J Cardio-Thoracic Surg 2014; 46: 699-705.</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Mohammad WA, Ashraf Z, Sayed HF. Urgent versus elective coronary artery bypass grafting in acute coronary artery syndrome. J Egypt Soc CardioThoracic Surg 2018; 26: 17-23.</mixed-citation><mixed-citation xml:lang="en">Mohammad WA, Ashraf Z, Sayed HF. Urgent versus elective coronary artery bypass grafting in acute coronary artery syndrome. J Egypt Soc CardioThoracic Surg 2018; 26: 17-23.</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Kwak YL, Kim JC, Choi YS, Yoo KJ, Song Y, Shim JK. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol 2010; 56: 1994-2002.</mixed-citation><mixed-citation xml:lang="en">Kwak YL, Kim JC, Choi YS, Yoo KJ, Song Y, Shim JK. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol 2010; 56: 1994-2002.</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Ranucci M, Baryshnikova E, Soro G, Ballotta A, De Benedetti D, Conti D; Surgical and Clinical Outcome Research (SCORE) Group. Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg 2011; 91: 123-129.</mixed-citation><mixed-citation xml:lang="en">Ranucci M, Baryshnikova E, Soro G, Ballotta A, De Benedetti D, Conti D; Surgical and Clinical Outcome Research (SCORE) Group. Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg 2011; 91: 123-129.</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Mahla E, Suarez TA, Bliden KP, Rehak P, Metzler H, Sequeira AJ, Cho P, Sell J, Fan J, Antonino MJ, Tantry US, Gurbel PA. Platelet function measurementbased strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrelassociated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 2012; 5: 261-269.</mixed-citation><mixed-citation xml:lang="en">Mahla E, Suarez TA, Bliden KP, Rehak P, Metzler H, Sequeira AJ, Cho P, Sell J, Fan J, Antonino MJ, Tantry US, Gurbel PA. Platelet function measurementbased strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrelassociated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 2012; 5: 261-269.</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Ranucci M, Colella D, Baryshnikova E, Di Dedda U; Surgical and Clinical Outcome Research (SCORE) Group. Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery. Br J Anaesth 2014; 113: 970-976.</mixed-citation><mixed-citation xml:lang="en">Ranucci M, Colella D, Baryshnikova E, Di Dedda U; Surgical and Clinical Outcome Research (SCORE) Group. Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery. Br J Anaesth 2014; 113: 970-976.</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Vries MJ, Bouman HJ, Olie RH, Veenstra LF, Zwaveling S, Verhezen PW, Ten Cate-Hoek AJ, Ten Cate H, Henskens YM, van der Meijden PE. Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients. Eur Heart J Cardiovasc Pharmacother 2017; 3: 11-17.</mixed-citation><mixed-citation xml:lang="en">Vries MJ, Bouman HJ, Olie RH, Veenstra LF, Zwaveling S, Verhezen PW, Ten Cate-Hoek AJ, Ten Cate H, Henskens YM, van der Meijden PE. Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients. Eur Heart J Cardiovasc Pharmacother 2017; 3: 11-17.</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Solo K, Lavi S, Choudhury T, et al. Pre-operative use of aspirin in patients undergoing coronary artery bypass grafting: a systematic review and updated meta-analysis. J Thorac Dis 2018; 10: 3444-3459.</mixed-citation><mixed-citation xml:lang="en">Solo K, Lavi S, Choudhury T, et al. Pre-operative use of aspirin in patients undergoing coronary artery bypass grafting: a systematic review and updated meta-analysis. J Thorac Dis 2018; 10: 3444-3459.</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Hwang D, Lee JM, Rhee TM, et al. The effects of preoperative aspirin on coronary artery bypass surgery: a systematic meta-analysis. Korean Circ J 2019; 49: 498-510.</mixed-citation><mixed-citation xml:lang="en">Hwang D, Lee JM, Rhee TM, et al. The effects of preoperative aspirin on coronary artery bypass surgery: a systematic meta-analysis. Korean Circ J 2019; 49: 498-510.</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Lim E, Ali Z, Ali A, Routledge T, Edmonds L, Altman DG, Large S. Indirect comparison meta-analysis of aspirin therapy after coronary surgery. BMJ 2003; 327: 1309.</mixed-citation><mixed-citation xml:lang="en">Lim E, Ali Z, Ali A, Routledge T, Edmonds L, Altman DG, Large S. Indirect comparison meta-analysis of aspirin therapy after coronary surgery. BMJ 2003; 327: 1309.</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation 1991; 83: 1526-1533.</mixed-citation><mixed-citation xml:lang="en">Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation 1991; 83: 1526-1533.</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">Chakos A, Jbara D, Singh K, Yan TD., Tian D. Network meta-analysis of antiplatelet therapy following coronary artery bypass grafting (CABG): none versus one versus two antiplatelet agents. Ann Cardiothorac Surg 2018; 7: 577-585.</mixed-citation><mixed-citation xml:lang="en">Chakos A, Jbara D, Singh K, Yan TD., Tian D. Network meta-analysis of antiplatelet therapy following coronary artery bypass grafting (CABG): none versus one versus two antiplatelet agents. Ann Cardiothorac Surg 2018; 7: 577-585.</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">Fox KA.A., Mehta SR., Peters R, Zhao F, Lakkis N, Gersh BJ., Yusuf S. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome. The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110: 1202-1208.</mixed-citation><mixed-citation xml:lang="en">Fox KA.A., Mehta SR., Peters R, Zhao F, Lakkis N, Gersh BJ., Yusuf S. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome. The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110: 1202-1208.</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">Sørensen R, Abildstrøm SZ., Hansen PR., Hvelplund A, Andersson C, Charlot M, Fosbøl EL., Køber L, Madsen JK., Gislason GH., Torp-Pedersen C. Efficacy of Post-Operative Clopidogrel Treatment in Patients Revascularized With Coronary Artery Bypass Grafting After Myocardial Infarction. J Am Coll Cardiol 2011; 57: 1202-1209.</mixed-citation><mixed-citation xml:lang="en">Sørensen R, Abildstrøm SZ., Hansen PR., Hvelplund A, Andersson C, Charlot M, Fosbøl EL., Køber L, Madsen JK., Gislason GH., Torp-Pedersen C. Efficacy of Post-Operative Clopidogrel Treatment in Patients Revascularized With Coronary Artery Bypass Grafting After Myocardial Infarction. J Am Coll Cardiol 2011; 57: 1202-1209.</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">Bomb R, Oliphant CS., Khouzam RN. Dual Antiplatelet Therapy after Coronary Artery Bypass Grafting in the Setting of Acute Coronary Syndrome. Am J Cardiol 2015; 116: 148-154.</mixed-citation><mixed-citation xml:lang="en">Bomb R, Oliphant CS., Khouzam RN. Dual Antiplatelet Therapy after Coronary Artery Bypass Grafting in the Setting of Acute Coronary Syndrome. Am J Cardiol 2015; 116: 148-154.</mixed-citation></citation-alternatives></ref><ref id="cit105"><label>105</label><citation-alternatives><mixed-citation xml:lang="ru">Ramanathan, K. Abel J.G., Park J.E., Anthony Fung A., Mathew V., Taylor C.M., Mancini G.B., Gao M., Ding L., Verma S., Humphries K.H., Farkouh M.E., et al. J Am Coll Cardiol. 2017;70(24):2995–3006.</mixed-citation><mixed-citation xml:lang="en">Ramanathan, K. Abel J.G., Park J.E., Anthony Fung A., Mathew V., Taylor C.M., Mancini G.B., Gao M., Ding L., Verma S., Humphries K.H., Farkouh M.E., et al. J Am Coll Cardiol. 2017;70(24):2995–3006.</mixed-citation></citation-alternatives></ref><ref id="cit106"><label>106</label><citation-alternatives><mixed-citation xml:lang="ru">Farkouh M.E, Domanski M., Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012;367: 2375–84.</mixed-citation><mixed-citation xml:lang="en">Farkouh M.E, Domanski M., Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012;367: 2375–84.</mixed-citation></citation-alternatives></ref><ref id="cit107"><label>107</label><citation-alternatives><mixed-citation xml:lang="ru">Ben-Gal Y, Mohr R, Feit F, et al. Surgical versus percutaneous coronary revascularization for multivessel disease in diabetic patients with nonST-segment-elevation acute coronary syndrome: analysis from the Acute Catheterization and Early Intervention Triage Strategy trial. Circ Cardiovasc Interv. 2015; 8</mixed-citation><mixed-citation xml:lang="en">Ben-Gal Y, Mohr R, Feit F, et al. Surgical versus percutaneous coronary revascularization for multivessel disease in diabetic patients with nonST-segment-elevation acute coronary syndrome: analysis from the Acute Catheterization and Early Intervention Triage Strategy trial. Circ Cardiovasc Interv. 2015; 8</mixed-citation></citation-alternatives></ref><ref id="cit108"><label>108</label><citation-alternatives><mixed-citation xml:lang="ru">Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller . CE, Jacobs AK, Slater JN, Col J, McKinlay SM, LeJemtel TH. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341: 625-634.</mixed-citation><mixed-citation xml:lang="en">Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller . CE, Jacobs AK, Slater JN, Col J, McKinlay SM, LeJemtel TH. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341: 625-634.</mixed-citation></citation-alternatives></ref><ref id="cit109"><label>109</label><citation-alternatives><mixed-citation xml:lang="ru">Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, Col J, White HD; SHOCK Investigators. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006; 295: 2511-2515.</mixed-citation><mixed-citation xml:lang="en">Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, Col J, White HD; SHOCK Investigators. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006; 295: 2511-2515.</mixed-citation></citation-alternatives></ref><ref id="cit110"><label>110</label><citation-alternatives><mixed-citation xml:lang="ru">Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J, Bohm M, Ebelt H, Schneider S, Schuler G, Werdan K, Investigators I-SIT. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367:1287-1296.</mixed-citation><mixed-citation xml:lang="en">Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J, Bohm M, Ebelt H, Schneider S, Schuler G, Werdan K, Investigators I-SIT. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367:1287-1296.</mixed-citation></citation-alternatives></ref><ref id="cit111"><label>111</label><citation-alternatives><mixed-citation xml:lang="ru">Hajjar, L.A., Teboul, J. Mechanical Circulatory Support Devices for Cardiogenic Shock: State of the Art. Crit Care 2019; 23: 76. https://doi.org/10.1186/s13054-019-2368-y</mixed-citation><mixed-citation xml:lang="en">Hajjar, L.A., Teboul, J. Mechanical Circulatory Support Devices for Cardiogenic Shock: State of the Art. Crit Care 2019; 23: 76. https://doi.org/10.1186/s13054-019-2368-y</mixed-citation></citation-alternatives></ref><ref id="cit112"><label>112</label><citation-alternatives><mixed-citation xml:lang="ru">Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-1860</mixed-citation><mixed-citation xml:lang="en">Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-1860</mixed-citation></citation-alternatives></ref><ref id="cit113"><label>113</label><citation-alternatives><mixed-citation xml:lang="ru">Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.</mixed-citation><mixed-citation xml:lang="en">Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.</mixed-citation></citation-alternatives></ref><ref id="cit114"><label>114</label><citation-alternatives><mixed-citation xml:lang="ru">Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Investigators PLATO. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057</mixed-citation><mixed-citation xml:lang="en">Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Investigators PLATO. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057</mixed-citation></citation-alternatives></ref><ref id="cit115"><label>115</label><citation-alternatives><mixed-citation xml:lang="ru">Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmbergt H, Zhao F, Chrolavicius S, Copland I, Fox KA, Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCICURE study. Lancet 2001;358:527-533.</mixed-citation><mixed-citation xml:lang="en">Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmbergt H, Zhao F, Chrolavicius S, Copland I, Fox KA, Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCICURE study. Lancet 2001;358:527-533.</mixed-citation></citation-alternatives></ref><ref id="cit116"><label>116</label><citation-alternatives><mixed-citation xml:lang="ru">Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flugel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Mollmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S,Allali A, Ndrepepa G, Schuhlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A,Tolg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A, ISAR-REACT 5 Trial Investigators. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 2019;381:1524-1534</mixed-citation><mixed-citation xml:lang="en">Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flugel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Mollmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S,Allali A, Ndrepepa G, Schuhlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A,Tolg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A, ISAR-REACT 5 Trial Investigators. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 2019;381:1524-1534</mixed-citation></citation-alternatives></ref><ref id="cit117"><label>117</label><citation-alternatives><mixed-citation xml:lang="ru">Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA, Investigators CHAMPION. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013;382:1981-1992</mixed-citation><mixed-citation xml:lang="en">Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA, Investigators CHAMPION. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013;382:1981-1992</mixed-citation></citation-alternatives></ref><ref id="cit118"><label>118</label><citation-alternatives><mixed-citation xml:lang="ru">Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, tenBerg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J, Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E, Widimsky P, ACCOAST Investigators. Pretreatment with prasugrel in non-STsegment elevation acute coronary syndromes. N Engl J Med 2013;369:999-1010.</mixed-citation><mixed-citation xml:lang="en">Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, tenBerg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J, Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E, Widimsky P, ACCOAST Investigators. Pretreatment with prasugrel in non-STsegment elevation acute coronary syndromes. N Engl J Med 2013;369:999-1010.</mixed-citation></citation-alternatives></ref><ref id="cit119"><label>119</label><citation-alternatives><mixed-citation xml:lang="ru">Anne Bellemain-Appaix, Stephen A O’Connor, Johanne Silvain, Michel Cucherat, Farzin Beygui, Olivier Barthélémy, Jean-Philippe Collet, Laurent Jacq, François Bernasconi, Gilles MontalescotJAMA, . 2012 Dec 19;308(23):2507-2516.</mixed-citation><mixed-citation xml:lang="en">Anne Bellemain-Appaix, Stephen A O’Connor, Johanne Silvain, Michel Cucherat, Farzin Beygui, Olivier Barthélémy, Jean-Philippe Collet, Laurent Jacq, François Bernasconi, Gilles MontalescotJAMA, . 2012 Dec 19;308(23):2507-2516.</mixed-citation></citation-alternatives></ref><ref id="cit120"><label>120</label><citation-alternatives><mixed-citation xml:lang="ru">Anne Bellemain-Appaix, Mathieu Kerneis, Stephen A O’Connor, Johanne Silvain, Michel Cucherat, Farzin Beygui, Olivier Barthélémy, Jean-Philippe Collet, Laurent Jacq, François Bernasconi, Gilles Montalescoty. BMJ 2014;349-361</mixed-citation><mixed-citation xml:lang="en">Anne Bellemain-Appaix, Mathieu Kerneis, Stephen A O’Connor, Johanne Silvain, Michel Cucherat, Farzin Beygui, Olivier Barthélémy, Jean-Philippe Collet, Laurent Jacq, François Bernasconi, Gilles Montalescoty. BMJ 2014;349-361</mixed-citation></citation-alternatives></ref><ref id="cit121"><label>121</label><citation-alternatives><mixed-citation xml:lang="ru">Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996;276:811-815.</mixed-citation><mixed-citation xml:lang="en">Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996;276:811-815.</mixed-citation></citation-alternatives></ref><ref id="cit122"><label>122</label><citation-alternatives><mixed-citation xml:lang="ru">Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355:1936-1942.</mixed-citation><mixed-citation xml:lang="en">Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355:1936-1942.</mixed-citation></citation-alternatives></ref><ref id="cit123"><label>123</label><citation-alternatives><mixed-citation xml:lang="ru">Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht HJ, Lopez-Sendon JL, Budaj A, Diaz R, Avezum A, Widimsky P, Rao SV, Chrolavicius S, Meeks B, Joyner C, Pogue J, Yusuf S. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA 2010;304: 1339–1349</mixed-citation><mixed-citation xml:lang="en">Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht HJ, Lopez-Sendon JL, Budaj A, Diaz R, Avezum A, Widimsky P, Rao SV, Chrolavicius S, Meeks B, Joyner C, Pogue J, Yusuf S. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA 2010;304: 1339–1349</mixed-citation></citation-alternatives></ref><ref id="cit124"><label>124</label><citation-alternatives><mixed-citation xml:lang="ru">Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, Braunwald E. Assessment of the treatment effect of enoxaparin for unstable angina/non-Qwave myocardial infarction. TIMI 11B-ESSENCE metaanalysis. Circulation 1999;100:1602-1608.</mixed-citation><mixed-citation xml:lang="en">Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, Braunwald E. Assessment of the treatment effect of enoxaparin for unstable angina/non-Qwave myocardial infarction. TIMI 11B-ESSENCE metaanalysis. Circulation 1999;100:1602-1608.</mixed-citation></citation-alternatives></ref><ref id="cit125"><label>125</label><citation-alternatives><mixed-citation xml:lang="ru">Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H, SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.</mixed-citation><mixed-citation xml:lang="en">Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H, SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.</mixed-citation></citation-alternatives></ref><ref id="cit126"><label>126</label><citation-alternatives><mixed-citation xml:lang="ru">Valgimigli M, Frigoli E, Leonardi S, Rothenbuhler M, Gagnor A, Calabro P, Garducci S, Rubartelli P, Briguori C, Ando G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N, Rigattieri S, Zingarelli A, Tosi P, van ’t Hof A, Boccuzzi G, Omerovic E, Sabate M, Heg D, Juni P, Vranckx P, MATRIX Investigators. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 2015;373:997-1009.</mixed-citation><mixed-citation xml:lang="en">Valgimigli M, Frigoli E, Leonardi S, Rothenbuhler M, Gagnor A, Calabro P, Garducci S, Rubartelli P, Briguori C, Ando G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N, Rigattieri S, Zingarelli A, Tosi P, van ’t Hof A, Boccuzzi G, Omerovic E, Sabate M, Heg D, Juni P, Vranckx P, MATRIX Investigators. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 2015;373:997-1009.</mixed-citation></citation-alternatives></ref><ref id="cit127"><label>127</label><citation-alternatives><mixed-citation xml:lang="ru">Jolly SS, Faxon DP, Fox KA, Afzal R, Boden WE, Widimsky P, Steg PG, Valentin V, Budaj A, Granger CB, Joyner CD, Chrolavicius S, Yusuf S, Mehta SR. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. J Am Coll Cardiol 2009;54:468–476</mixed-citation><mixed-citation xml:lang="en">Jolly SS, Faxon DP, Fox KA, Afzal R, Boden WE, Widimsky P, Steg PG, Valentin V, Budaj A, Granger CB, Joyner CD, Chrolavicius S, Yusuf S, Mehta SR. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. J Am Coll Cardiol 2009;54:468–476</mixed-citation></citation-alternatives></ref><ref id="cit128"><label>128</label><citation-alternatives><mixed-citation xml:lang="ru">Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M, PRECISE-DAPT Stud Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individualpatient datasets from clinical trials. Lancet 2017;389:1025-1034</mixed-citation><mixed-citation xml:lang="en">Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M, PRECISE-DAPT Stud Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individualpatient datasets from clinical trials. Lancet 2017;389:1025-1034</mixed-citation></citation-alternatives></ref><ref id="cit129"><label>129</label><citation-alternatives><mixed-citation xml:lang="ru">John D. McClure, Jennifer C. Ramsay, Colin Berry. Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All􏰅Cause Mortality in Clinical Trials of Time􏰅Constrained Dual􏰅Antiplatelet Therapy After Percutaneous Coronary Intervention. J Am Heart Assoc. 2020 Aug 18; 9(16): e017109. https://doi.org/10.1161/JAHA.120.017109</mixed-citation><mixed-citation xml:lang="en">John D. McClure, Jennifer C. Ramsay, Colin Berry. Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All􏰅Cause Mortality in Clinical Trials of Time􏰅Constrained Dual􏰅Antiplatelet Therapy After Percutaneous Coronary Intervention. J Am Heart Assoc. 2020 Aug 18; 9(16): e017109. https://doi.org/10.1161/JAHA.120.017109</mixed-citation></citation-alternatives></ref><ref id="cit130"><label>130</label><citation-alternatives><mixed-citation xml:lang="ru">Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM, ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9–19</mixed-citation><mixed-citation xml:lang="en">Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM, ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9–19</mixed-citation></citation-alternatives></ref><ref id="cit131"><label>131</label><citation-alternatives><mixed-citation xml:lang="ru">Thomas Cuisset, Pierre Deharo, Jacques Quilici et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. European Heart Journal (2017) 0, 1–9. https://doi.org/10.1093/eurheartj/ehx175</mixed-citation><mixed-citation xml:lang="en">Thomas Cuisset, Pierre Deharo, Jacques Quilici et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. European Heart Journal (2017) 0, 1–9. https://doi.org/10.1093/eurheartj/ehx175</mixed-citation></citation-alternatives></ref><ref id="cit132"><label>132</label><citation-alternatives><mixed-citation xml:lang="ru">Sibbing D et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial Lancet 2017 Aug; 390:1747-57</mixed-citation><mixed-citation xml:lang="en">Sibbing D et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial Lancet 2017 Aug; 390:1747-57</mixed-citation></citation-alternatives></ref><ref id="cit133"><label>133</label><citation-alternatives><mixed-citation xml:lang="ru">Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van ’t Hof AWJ, van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, Mosterd A, Herrman JR, Dewilde WJM, Janssen PWA, Kelder JC, Postma MJ, de Boer A, Boersma C, Deneer VHM, Ten Berg JM. A genotypeguided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med 2019;381:1621-1631.</mixed-citation><mixed-citation xml:lang="en">Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van ’t Hof AWJ, van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, Mosterd A, Herrman JR, Dewilde WJM, Janssen PWA, Kelder JC, Postma MJ, de Boer A, Boersma C, Deneer VHM, Ten Berg JM. A genotypeguided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med 2019;381:1621-1631.</mixed-citation></citation-alternatives></ref><ref id="cit134"><label>134</label><citation-alternatives><mixed-citation xml:lang="ru">Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj, A, Theroux, P, Ruda, M, Hamm, C, Goto, S, Spinar, J, Nicolau, JC, Kiss, RG, Murphy, SA, Wiviott, SD, Held, P, Braunwald, E, Sabatine, MS, PEGASUSTIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-1800</mixed-citation><mixed-citation xml:lang="en">Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj, A, Theroux, P, Ruda, M, Hamm, C, Goto, S, Spinar, J, Nicolau, JC, Kiss, RG, Murphy, SA, Wiviott, SD, Held, P, Braunwald, E, Sabatine, MS, PEGASUSTIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-1800</mixed-citation></citation-alternatives></ref><ref id="cit135"><label>135</label><citation-alternatives><mixed-citation xml:lang="ru">Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Jr., Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM, DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155-2166.</mixed-citation><mixed-citation xml:lang="en">Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Jr., Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM, DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155-2166.</mixed-citation></citation-alternatives></ref><ref id="cit136"><label>136</label><citation-alternatives><mixed-citation xml:lang="ru">Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez- Jaramillo P, O’Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Stork S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S, COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377:1319-1330.</mixed-citation><mixed-citation xml:lang="en">Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez- Jaramillo P, O’Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Stork S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S, COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377:1319-1330.</mixed-citation></citation-alternatives></ref><ref id="cit137"><label>137</label><citation-alternatives><mixed-citation xml:lang="ru">Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, Christensen CB, Lip GY, Kober L, Torp-Pedersen C, Hansen ML. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013;62:981–989.</mixed-citation><mixed-citation xml:lang="en">Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, Christensen CB, Lip GY, Kober L, Torp-Pedersen C, Hansen ML. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013;62:981–989.</mixed-citation></citation-alternatives></ref><ref id="cit138"><label>138</label><citation-alternatives><mixed-citation xml:lang="ru">Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D, Hoppmann P, Schneider S, Fusaro M, Ott I, Kristensen SD, Ibrahim T, Massberg S, Schunkert H, Laugwitz KL, Kastrati A, Sarafoff N. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: The ISAR-TRIPLE trial. J Am Coll Cardiol 2015;65:1619–1629</mixed-citation><mixed-citation xml:lang="en">Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D, Hoppmann P, Schneider S, Fusaro M, Ott I, Kristensen SD, Ibrahim T, Massberg S, Schunkert H, Laugwitz KL, Kastrati A, Sarafoff N. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: The ISAR-TRIPLE trial. J Am Coll Cardiol 2015;65:1619–1629</mixed-citation></citation-alternatives></ref><ref id="cit139"><label>139</label><citation-alternatives><mixed-citation xml:lang="ru">Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van ’t Hof AW, ten Berg JM: WOEST Study Investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013;381:1107–1115.</mixed-citation><mixed-citation xml:lang="en">Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van ’t Hof AW, ten Berg JM: WOEST Study Investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013;381:1107–1115.</mixed-citation></citation-alternatives></ref><ref id="cit140"><label>140</label><citation-alternatives><mixed-citation xml:lang="ru">Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:2423–2434.</mixed-citation><mixed-citation xml:lang="en">Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:2423–2434.</mixed-citation></citation-alternatives></ref><ref id="cit141"><label>141</label><citation-alternatives><mixed-citation xml:lang="ru">Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH; RE-DUAL Steering Committee PCI and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:1513–1524</mixed-citation><mixed-citation xml:lang="en">Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH; RE-DUAL Steering Committee PCI and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:1513–1524</mixed-citation></citation-alternatives></ref><ref id="cit142"><label>142</label><citation-alternatives><mixed-citation xml:lang="ru">Renato D. Lopes, Gretchen Heizer, Ronald Aronson, Amit N. Vora, Tyler Massaro, Roxana Mehran, Shaun G. Goodman, Stephan Windecker, Harald Darius, Jia Li, Ph.D., Oleg Averkov, M. Cecilia Bahit, Otavio Berwanger, Andrzej Budaj, Ziad Hijazi, M.D., Ph.D., Alexander Parkhomenko, Peter Sinnaeve, Robert F. Storey, Holger Thiele, Dragos Vinereanu, Christopher B. Granger, John H. Alexander, for the AUGUSTUS Investigators. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. NEJM. org. https://doi.org/10.1056/NEJMoa1817083</mixed-citation><mixed-citation xml:lang="en">Renato D. Lopes, Gretchen Heizer, Ronald Aronson, Amit N. Vora, Tyler Massaro, Roxana Mehran, Shaun G. Goodman, Stephan Windecker, Harald Darius, Jia Li, Ph.D., Oleg Averkov, M. Cecilia Bahit, Otavio Berwanger, Andrzej Budaj, Ziad Hijazi, M.D., Ph.D., Alexander Parkhomenko, Peter Sinnaeve, Robert F. Storey, Holger Thiele, Dragos Vinereanu, Christopher B. Granger, John H. Alexander, for the AUGUSTUS Investigators. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. NEJM. org. https://doi.org/10.1056/NEJMoa1817083</mixed-citation></citation-alternatives></ref><ref id="cit143"><label>143</label><citation-alternatives><mixed-citation xml:lang="ru">2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). European Heart Journal (2020) 00, 1-126 https://doi.org/10.1093/eurheartj/ehaa612</mixed-citation><mixed-citation xml:lang="en">2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). European Heart Journal (2020) 00, 1-126 https://doi.org/10.1093/eurheartj/ehaa612</mixed-citation></citation-alternatives></ref><ref id="cit144"><label>144</label><citation-alternatives><mixed-citation xml:lang="ru">Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, Stankowska K, Buszko K, Navarese EP, Jilma B, Siller-Matula JM, Marszall MP, Rosc D, Kozinski M. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, doubleblind, placebo-controlled IMPRESSION trial. Eur Heart J 2016; 37: 245-252.</mixed-citation><mixed-citation xml:lang="en">Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, Stankowska K, Buszko K, Navarese EP, Jilma B, Siller-Matula JM, Marszall MP, Rosc D, Kozinski M. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, doubleblind, placebo-controlled IMPRESSION trial. Eur Heart J 2016; 37: 245-252.</mixed-citation></citation-alternatives></ref><ref id="cit145"><label>145</label><citation-alternatives><mixed-citation xml:lang="ru">Silvain J, Storey RF, Cayla G, Esteve JB, Dillinger JG, Rousseau H, et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction: the PRIVATEATLANTIC study. Thromb Haemost 2016; 116: 369–378.</mixed-citation><mixed-citation xml:lang="en">Silvain J, Storey RF, Cayla G, Esteve JB, Dillinger JG, Rousseau H, et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction: the PRIVATEATLANTIC study. Thromb Haemost 2016; 116: 369–378.</mixed-citation></citation-alternatives></ref><ref id="cit146"><label>146</label><citation-alternatives><mixed-citation xml:lang="ru">Kubica J., Kubica A., Jilma B., Adamski P., et al. Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. Int J Cardiol 2016; 215: 201-208.</mixed-citation><mixed-citation xml:lang="en">Kubica J., Kubica A., Jilma B., Adamski P., et al. Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. Int J Cardiol 2016; 215: 201-208.</mixed-citation></citation-alternatives></ref><ref id="cit147"><label>147</label><citation-alternatives><mixed-citation xml:lang="ru">McEvoy J.W., Ibrahim K., Kickler T.S., Clarke W.A., et al. Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention. The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl). Circulation. 2018; 137: 307–309.</mixed-citation><mixed-citation xml:lang="en">McEvoy J.W., Ibrahim K., Kickler T.S., Clarke W.A., et al. Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention. The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl). Circulation. 2018; 137: 307–309.</mixed-citation></citation-alternatives></ref><ref id="cit148"><label>148</label><citation-alternatives><mixed-citation xml:lang="ru">Stub D., Smith K., Bernard S., Nehme Z., Stephenson M., Bray J.E., Cameron P., Barger B., Ellims A.H., Taylor A.J., Meredith I.T., Kaye D.M., AVOID Investigators. Air versus oxygen in ST-segment-elevation myocardial infarction. Circulation 2015; 131: 2143-2150.</mixed-citation><mixed-citation xml:lang="en">Stub D., Smith K., Bernard S., Nehme Z., Stephenson M., Bray J.E., Cameron P., Barger B., Ellims A.H., Taylor A.J., Meredith I.T., Kaye D.M., AVOID Investigators. Air versus oxygen in ST-segment-elevation myocardial infarction. Circulation 2015; 131: 2143-2150.</mixed-citation></citation-alternatives></ref><ref id="cit149"><label>149</label><citation-alternatives><mixed-citation xml:lang="ru">Leizorovicz A, Lechat P, Cucherat M, Bugnard F. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebocontrolled studies_CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J 2002;143:301_307.</mixed-citation><mixed-citation xml:lang="en">Leizorovicz A, Lechat P, Cucherat M, Bugnard F. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebocontrolled studies_CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J 2002;143:301_307.</mixed-citation></citation-alternatives></ref><ref id="cit150"><label>150</label><citation-alternatives><mixed-citation xml:lang="ru">Andersson C, Shilane D, Go AS, Chang TI, Kazi D, Solomon MD, Boothroyd DB, Hlatky MA. Beta-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol 2014;64:247_252.</mixed-citation><mixed-citation xml:lang="en">Andersson C, Shilane D, Go AS, Chang TI, Kazi D, Solomon MD, Boothroyd DB, Hlatky MA. Beta-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol 2014;64:247_252.</mixed-citation></citation-alternatives></ref><ref id="cit151"><label>151</label><citation-alternatives><mixed-citation xml:lang="ru">Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, Montalescot G, Hsu A, Fox KA, Lincoff AM. Beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes 2014;7:872_881.</mixed-citation><mixed-citation xml:lang="en">Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, Montalescot G, Hsu A, Fox KA, Lincoff AM. Beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes 2014;7:872_881.</mixed-citation></citation-alternatives></ref><ref id="cit152"><label>152</label><citation-alternatives><mixed-citation xml:lang="ru">Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730_1737.</mixed-citation><mixed-citation xml:lang="en">Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730_1737.</mixed-citation></citation-alternatives></ref><ref id="cit153"><label>153</label><citation-alternatives><mixed-citation xml:lang="ru">Hwang D, Lee JM, Kim HK, Choi KH, Rhee TM, Park J, Park TK, Yang JH, Song YB, Choi JH, Hahn JY, Choi SH, Koo BK, Kim YJ, Chae SC, Cho MC, Kim CJ, Gwon HC, Jeong MH, Kim HS, KAMIR Investigators. Prognostic impact of betablocker dose after acute myocardial infarction. Circ J 2019;83:410_417.</mixed-citation><mixed-citation xml:lang="en">Hwang D, Lee JM, Kim HK, Choi KH, Rhee TM, Park J, Park TK, Yang JH, Song YB, Choi JH, Hahn JY, Choi SH, Koo BK, Kim YJ, Chae SC, Cho MC, Kim CJ, Gwon HC, Jeong MH, Kim HS, KAMIR Investigators. Prognostic impact of betablocker dose after acute myocardial infarction. Circ J 2019;83:410_417.</mixed-citation></citation-alternatives></ref><ref id="cit154"><label>154</label><citation-alternatives><mixed-citation xml:lang="ru">Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349_1355.</mixed-citation><mixed-citation xml:lang="en">Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349_1355.</mixed-citation></citation-alternatives></ref><ref id="cit155"><label>155</label><citation-alternatives><mixed-citation xml:lang="ru">Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A, Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 2003;362:7_</mixed-citation><mixed-citation xml:lang="en">Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A, Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 2003;362:7_</mixed-citation></citation-alternatives></ref><ref id="cit156"><label>156</label><citation-alternatives><mixed-citation xml:lang="ru">Hwang D, Lee JM, Kim HK, Choi KH, Rhee TM, Park J, Park TK, Yang JH, Song YB, Choi JH, Hahn JY, Choi SH, Koo BK, Kim YJ, Chae SC, Cho MC, Kim CJ, Gwon HC, Jeong MH, Kim HS, KAMIR Investigators. Prognostic impact of betablocker dose after acute myocardial infarction. Circ J 2019;83:410_417.</mixed-citation><mixed-citation xml:lang="en">Hwang D, Lee JM, Kim HK, Choi KH, Rhee TM, Park J, Park TK, Yang JH, Song YB, Choi JH, Hahn JY, Choi SH, Koo BK, Kim YJ, Chae SC, Cho MC, Kim CJ, Gwon HC, Jeong MH, Kim HS, KAMIR Investigators. Prognostic impact of betablocker dose after acute myocardial infarction. Circ J 2019;83:410_417.</mixed-citation></citation-alternatives></ref><ref id="cit157"><label>157</label><citation-alternatives><mixed-citation xml:lang="ru">Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, Montalescot G, Hsu A, Fox KA, Lincoff AM. Beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes 2014;7:872_881.</mixed-citation><mixed-citation xml:lang="en">Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, Montalescot G, Hsu A, Fox KA, Lincoff AM. Beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes 2014;7:872_881.</mixed-citation></citation-alternatives></ref><ref id="cit158"><label>158</label><citation-alternatives><mixed-citation xml:lang="ru">Puymirat E, Riant E, Aissaoui N, Soria A, Ducrocq G, Coste P, Cottin Y, Aupetit JF, Bonnefoy E, Blanchard D, Cattan S, Steg G, Schiele F, Ferrieres J, Juilliere Y, Simon T, Danchin N. Beta blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ 2016;354:i4801.</mixed-citation><mixed-citation xml:lang="en">Puymirat E, Riant E, Aissaoui N, Soria A, Ducrocq G, Coste P, Cottin Y, Aupetit JF, Bonnefoy E, Blanchard D, Cattan S, Steg G, Schiele F, Ferrieres J, Juilliere Y, Simon T, Danchin N. Beta blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ 2016;354:i4801.</mixed-citation></citation-alternatives></ref><ref id="cit159"><label>159</label><citation-alternatives><mixed-citation xml:lang="ru">Neumann A, Maura G, Weill A, Alla F, Danchin N. Clinical events after discontinuation of beta-blockers in patients without heart failure optimally treated after acute myocardial infarction: a cohort study on the French healthcare databases. Circ Cardiovasc Qual Outcomes 2018;11:e004356.</mixed-citation><mixed-citation xml:lang="en">Neumann A, Maura G, Weill A, Alla F, Danchin N. Clinical events after discontinuation of beta-blockers in patients without heart failure optimally treated after acute myocardial infarction: a cohort study on the French healthcare databases. Circ Cardiovasc Qual Outcomes 2018;11:e004356.</mixed-citation></citation-alternatives></ref><ref id="cit160"><label>160</label><citation-alternatives><mixed-citation xml:lang="ru">Kernis SJ, Harjai KJ, Stone GW, Grines LL, Boura JA, O’Neill WW, Grines CL. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol 2004;43:1773_1779.</mixed-citation><mixed-citation xml:lang="en">Kernis SJ, Harjai KJ, Stone GW, Grines LL, Boura JA, O’Neill WW, Grines CL. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol 2004;43:1773_1779.</mixed-citation></citation-alternatives></ref><ref id="cit161"><label>161</label><citation-alternatives><mixed-citation xml:lang="ru">Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD, DiNicolantonio JJ, Devereaux PJ, Alexander KP, Wetterslev J, Messerli FH. Clinical outcomes with beta-blockers for myocardial infarction: a metaanalysis of randomized trials. Am J Med 2014;127:939_953.</mixed-citation><mixed-citation xml:lang="en">Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD, DiNicolantonio JJ, Devereaux PJ, Alexander KP, Wetterslev J, Messerli FH. Clinical outcomes with beta-blockers for myocardial infarction: a metaanalysis of randomized trials. Am J Med 2014;127:939_953.</mixed-citation></citation-alternatives></ref><ref id="cit162"><label>162</label><citation-alternatives><mixed-citation xml:lang="ru">Dahl Aarvik M, Sandven I, Dondo TB, Gale CP, Ruddox V, Munkhaugen J, Atar D, Otterstad JE. Effect of oral beta-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2019;5:12_20.</mixed-citation><mixed-citation xml:lang="en">Dahl Aarvik M, Sandven I, Dondo TB, Gale CP, Ruddox V, Munkhaugen J, Atar D, Otterstad JE. Effect of oral beta-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2019;5:12_20.</mixed-citation></citation-alternatives></ref><ref id="cit163"><label>163</label><citation-alternatives><mixed-citation xml:lang="ru">Hong J, Barry AR. Long-term beta-blocker therapy after myocardial infarction in the reperfusion era: a systematic review. Pharmacotherapy 2018;38:546_554.</mixed-citation><mixed-citation xml:lang="en">Hong J, Barry AR. Long-term beta-blocker therapy after myocardial infarction in the reperfusion era: a systematic review. Pharmacotherapy 2018;38:546_554.</mixed-citation></citation-alternatives></ref><ref id="cit164"><label>164</label><citation-alternatives><mixed-citation xml:lang="ru">Puymirat E, Riant E, Aissaoui N, Soria A, Ducrocq G, Coste P, Cottin Y, Aupetit JF, Bonnefoy E, Blanchard D, Cattan S, Steg G, Schiele F, Ferrieres J, Juilliere Y, Simon T, Danchin N. Beta blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ 2016;354:i4801.</mixed-citation><mixed-citation xml:lang="en">Puymirat E, Riant E, Aissaoui N, Soria A, Ducrocq G, Coste P, Cottin Y, Aupetit JF, Bonnefoy E, Blanchard D, Cattan S, Steg G, Schiele F, Ferrieres J, Juilliere Y, Simon T, Danchin N. Beta blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ 2016;354:i4801.</mixed-citation></citation-alternatives></ref><ref id="cit165"><label>165</label><citation-alternatives><mixed-citation xml:lang="ru">Tsujimoto T, Kajio H, Shapiro MF, Sugiyama T. Risk of all-cause mortality in diabetic patients taking beta-blockers. Mayo Clin Proc 2018;93:409_418.</mixed-citation><mixed-citation xml:lang="en">Tsujimoto T, Kajio H, Shapiro MF, Sugiyama T. Risk of all-cause mortality in diabetic patients taking beta-blockers. Mayo Clin Proc 2018;93:409_418.</mixed-citation></citation-alternatives></ref><ref id="cit166"><label>166</label><citation-alternatives><mixed-citation xml:lang="ru">Neumann A, Maura G, Weill A, Alla F, Danchin N. Clinical events after discontinuation of beta-blockers in patients without heart failure optimally treated after acute myocardial infarction: a cohort study on the French healthcare databases. Circ Cardiovasc Qual Outcomes 2018;11:e004356.</mixed-citation><mixed-citation xml:lang="en">Neumann A, Maura G, Weill A, Alla F, Danchin N. Clinical events after discontinuation of beta-blockers in patients without heart failure optimally treated after acute myocardial infarction: a cohort study on the French healthcare databases. Circ Cardiovasc Qual Outcomes 2018;11:e004356.</mixed-citation></citation-alternatives></ref><ref id="cit167"><label>167</label><citation-alternatives><mixed-citation xml:lang="ru">Kontos M.C., Diercks D.B., Ho P.M., Wang T.Y., Chen A.Y., Roe M.T..Treatment and outcomes in patients with myocardial infarction treated with acute beta-blocker therapy: results from the American College of Cardiology’s NCDR(VR ). Am Heart J 2011; 161: 864-870.</mixed-citation><mixed-citation xml:lang="en">Kontos M.C., Diercks D.B., Ho P.M., Wang T.Y., Chen A.Y., Roe M.T..Treatment and outcomes in patients with myocardial infarction treated with acute beta-blocker therapy: results from the American College of Cardiology’s NCDR(VR ). Am Heart J 2011; 161: 864-870.</mixed-citation></citation-alternatives></ref><ref id="cit168"><label>168</label><citation-alternatives><mixed-citation xml:lang="ru">Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ, ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407_477.</mixed-citation><mixed-citation xml:lang="en">Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ, ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407_477.</mixed-citation></citation-alternatives></ref><ref id="cit169"><label>169</label><citation-alternatives><mixed-citation xml:lang="ru">Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575_1581.</mixed-citation><mixed-citation xml:lang="en">Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575_1581.</mixed-citation></citation-alternatives></ref><ref id="cit170"><label>170</label><citation-alternatives><mixed-citation xml:lang="ru">SOLVD Investigators Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293_302.</mixed-citation><mixed-citation xml:lang="en">SOLVD Investigators Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293_302.</mixed-citation></citation-alternatives></ref><ref id="cit171"><label>171</label><citation-alternatives><mixed-citation xml:lang="ru">Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr., Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669_677.</mixed-citation><mixed-citation xml:lang="en">Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr., Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669_677.</mixed-citation></citation-alternatives></ref><ref id="cit172"><label>172</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.</mixed-citation><mixed-citation xml:lang="en">Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.</mixed-citation></citation-alternatives></ref><ref id="cit173"><label>173</label><citation-alternatives><mixed-citation xml:lang="ru">Fox KM; European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.</mixed-citation><mixed-citation xml:lang="en">Fox KM; European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.</mixed-citation></citation-alternatives></ref><ref id="cit174"><label>174</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.</mixed-citation><mixed-citation xml:lang="en">Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.</mixed-citation></citation-alternatives></ref><ref id="cit175"><label>175</label><citation-alternatives><mixed-citation xml:lang="ru">Bangalore S, Fakheri R, Wandel S, Toklu B, Wandel J, Messerli FH. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ 2017; 356: j4.</mixed-citation><mixed-citation xml:lang="en">Bangalore S, Fakheri R, Wandel S, Toklu B, Wandel J, Messerli FH. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ 2017; 356: j4.</mixed-citation></citation-alternatives></ref><ref id="cit176"><label>176</label><citation-alternatives><mixed-citation xml:lang="ru">Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309_1321.</mixed-citation><mixed-citation xml:lang="en">Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309_1321.</mixed-citation></citation-alternatives></ref><ref id="cit177"><label>177</label><citation-alternatives><mixed-citation xml:lang="ru">Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111_188.</mixed-citation><mixed-citation xml:lang="en">Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111_188.</mixed-citation></citation-alternatives></ref><ref id="cit178"><label>178</label><citation-alternatives><mixed-citation xml:lang="ru">Cholesterol Treatment Trialists’ (CTT) Collaborators Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117_125.</mixed-citation><mixed-citation xml:lang="en">Cholesterol Treatment Trialists’ (CTT) Collaborators Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117_125.</mixed-citation></citation-alternatives></ref><ref id="cit179"><label>179</label><citation-alternatives><mixed-citation xml:lang="ru">Cholesterol Treatment Trialists’ (CTT) Collaboration Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670_1681.</mixed-citation><mixed-citation xml:lang="en">Cholesterol Treatment Trialists’ (CTT) Collaboration Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670_1681.</mixed-citation></citation-alternatives></ref><ref id="cit180"><label>180</label><citation-alternatives><mixed-citation xml:lang="ru">Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM, ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:2097_2107.</mixed-citation><mixed-citation xml:lang="en">Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM, ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:2097_2107.</mixed-citation></citation-alternatives></ref><ref id="cit181"><label>181</label><citation-alternatives><mixed-citation xml:lang="ru">Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713_1722.</mixed-citation><mixed-citation xml:lang="en">Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713_1722.</mixed-citation></citation-alternatives></ref><ref id="cit182"><label>182</label><citation-alternatives><mixed-citation xml:lang="ru">Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372: 2387_2397.</mixed-citation><mixed-citation xml:lang="en">Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372: 2387_2397.</mixed-citation></citation-alternatives></ref><ref id="cit183"><label>183</label><citation-alternatives><mixed-citation xml:lang="ru">Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713_1722.</mixed-citation><mixed-citation xml:lang="en">Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713_1722.</mixed-citation></citation-alternatives></ref><ref id="cit184"><label>184</label><citation-alternatives><mixed-citation xml:lang="ru">Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN, ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213_260.</mixed-citation><mixed-citation xml:lang="en">Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN, ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213_260.</mixed-citation></citation-alternatives></ref><ref id="cit185"><label>185</label><citation-alternatives><mixed-citation xml:lang="ru">Study Investigators NICE-SUGAR, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hebert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283_1297.</mixed-citation><mixed-citation xml:lang="en">Study Investigators NICE-SUGAR, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hebert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283_1297.</mixed-citation></citation-alternatives></ref><ref id="cit186"><label>186</label><citation-alternatives><mixed-citation xml:lang="ru">ORIGIN Trial Investigators Mellbin LG, Ryden L, Riddle MC, Probstfield J, Rosenstock J, Diaz R, Yusuf S, Gerstein HC. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 2013;34:3137_3144.</mixed-citation><mixed-citation xml:lang="en">ORIGIN Trial Investigators Mellbin LG, Ryden L, Riddle MC, Probstfield J, Rosenstock J, Diaz R, Yusuf S, Gerstein HC. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 2013;34:3137_3144.</mixed-citation></citation-alternatives></ref><ref id="cit187"><label>187</label><citation-alternatives><mixed-citation xml:lang="ru">ORIGIN Trial Investigators. Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial. Diabetes Care 2015;38:22_28.</mixed-citation><mixed-citation xml:lang="en">ORIGIN Trial Investigators. Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial. Diabetes Care 2015;38:22_28.</mixed-citation></citation-alternatives></ref><ref id="cit188"><label>188</label><citation-alternatives><mixed-citation xml:lang="ru">Iqbal A, Heller S. Managing hypoglycaemia. Best Pract Res Clin Endocrinol Metab 2016;30:413-430.</mixed-citation><mixed-citation xml:lang="en">Iqbal A, Heller S. Managing hypoglycaemia. Best Pract Res Clin Endocrinol Metab 2016;30:413-430.</mixed-citation></citation-alternatives></ref><ref id="cit189"><label>189</label><citation-alternatives><mixed-citation xml:lang="ru">Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pratley RE, Woo V, Heller S, Lange M, Brown-Frandsen K, Moses A, Barner Lekdorf J, Lehmann L, Kvist K, Buse JB, DEVOTE Study Group. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia 2018;61:58_65.</mixed-citation><mixed-citation xml:lang="en">Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pratley RE, Woo V, Heller S, Lange M, Brown-Frandsen K, Moses A, Barner Lekdorf J, Lehmann L, Kvist K, Buse JB, DEVOTE Study Group. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia 2018;61:58_65.</mixed-citation></citation-alternatives></ref><ref id="cit190"><label>190</label><citation-alternatives><mixed-citation xml:lang="ru">Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997;314:1512_1515.</mixed-citation><mixed-citation xml:lang="en">Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997;314:1512_1515.</mixed-citation></citation-alternatives></ref><ref id="cit191"><label>191</label><citation-alternatives><mixed-citation xml:lang="ru">Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57_65.</mixed-citation><mixed-citation xml:lang="en">Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57_65.</mixed-citation></citation-alternatives></ref><ref id="cit192"><label>192</label><citation-alternatives><mixed-citation xml:lang="ru">Ritsinger V, Malmberg K, Martensson A, Ryden L, Wedel H, Norhammar A. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. Lancet Diabetes Endocrinol 2014;2:627_633.</mixed-citation><mixed-citation xml:lang="en">Ritsinger V, Malmberg K, Martensson A, Ryden L, Wedel H, Norhammar A. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. Lancet Diabetes Endocrinol 2014;2:627_633.</mixed-citation></citation-alternatives></ref><ref id="cit193"><label>193</label><citation-alternatives><mixed-citation xml:lang="ru">Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580_591.</mixed-citation><mixed-citation xml:lang="en">Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580_591.</mixed-citation></citation-alternatives></ref><ref id="cit194"><label>194</label><citation-alternatives><mixed-citation xml:lang="ru">Gyberg V, De Bacquer D, De Backer G, Jennings C, Kotseva K, Mellbin L, Schnell O, Tuomilehto J, Wood D, Ryden L, Amouyel P, Bruthans J, Conde AC, Cifkova R, Deckers JW, De Sutter J, Dilic M, Dolzhenko M, Erglis A, Fras Z, Gaita D, Gotcheva N, Goudevenos J, Heuschmann P, Laucevicius A, Lehto S, Lovic D, Milicic D, Moore D, Nicolaides E, Oganov R, Pajak A, Pogosova N, Reiner Z, Stagmo M, Stork S, Tokgozoglu L, Vulic D, EUROASPIRE Investigators. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovasc Diabetol 2015;14:133.</mixed-citation><mixed-citation xml:lang="en">Gyberg V, De Bacquer D, De Backer G, Jennings C, Kotseva K, Mellbin L, Schnell O, Tuomilehto J, Wood D, Ryden L, Amouyel P, Bruthans J, Conde AC, Cifkova R, Deckers JW, De Sutter J, Dilic M, Dolzhenko M, Erglis A, Fras Z, Gaita D, Gotcheva N, Goudevenos J, Heuschmann P, Laucevicius A, Lehto S, Lovic D, Milicic D, Moore D, Nicolaides E, Oganov R, Pajak A, Pogosova N, Reiner Z, Stagmo M, Stork S, Tokgozoglu L, Vulic D, EUROASPIRE Investigators. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovasc Diabetol 2015;14:133.</mixed-citation></citation-alternatives></ref><ref id="cit195"><label>195</label><citation-alternatives><mixed-citation xml:lang="ru">Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T, J-DOIT3 Study Group. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (JDOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2017;5:951_964.</mixed-citation><mixed-citation xml:lang="en">Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T, J-DOIT3 Study Group. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (JDOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2017;5:951_964.</mixed-citation></citation-alternatives></ref><ref id="cit196"><label>196</label><citation-alternatives><mixed-citation xml:lang="ru">Oellgaard J, Gaede P, Rossing P, Rorth R, Kober L, Parving HH, Pedersen O. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia 2018;61:1724_1733.</mixed-citation><mixed-citation xml:lang="en">Oellgaard J, Gaede P, Rossing P, Rorth R, Kober L, Parving HH, Pedersen O. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia 2018;61:1724_1733.</mixed-citation></citation-alternatives></ref><ref id="cit197"><label>197</label><citation-alternatives><mixed-citation xml:lang="ru">Rawshani A, Rawshani A, Franzen S, Sattar N, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbjornsdottir S. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2018;379:633_644.</mixed-citation><mixed-citation xml:lang="en">Rawshani A, Rawshani A, Franzen S, Sattar N, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbjornsdottir S. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2018;379:633_644.</mixed-citation></citation-alternatives></ref><ref id="cit198"><label>198</label><citation-alternatives><mixed-citation xml:lang="ru">Miller-Hodges E, Anand A, Shah ASV, Chapman AR, Gallacher P, Lee KK, Farrah T, Halbesma N, Blackmur JP, Newby DE, Mills NL, Dhaun N. Highsensitivity cardiac troponin and the risk stratification of patients with renal impairment presenting with suspected acute coronary syndrome. Circulation 2018; 137: 425-435.</mixed-citation><mixed-citation xml:lang="en">Miller-Hodges E, Anand A, Shah ASV, Chapman AR, Gallacher P, Lee KK, Farrah T, Halbesma N, Blackmur JP, Newby DE, Mills NL, Dhaun N. Highsensitivity cardiac troponin and the risk stratification of patients with renal impairment presenting with suspected acute coronary syndrome. Circulation 2018; 137: 425-435.</mixed-citation></citation-alternatives></ref><ref id="cit199"><label>199</label><citation-alternatives><mixed-citation xml:lang="ru">Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, Wallentin L, Jernberg T, SWEDEHEART. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation 2009; 120: 851-858.</mixed-citation><mixed-citation xml:lang="en">Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, Wallentin L, Jernberg T, SWEDEHEART. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation 2009; 120: 851-858.</mixed-citation></citation-alternatives></ref><ref id="cit200"><label>200</label><citation-alternatives><mixed-citation xml:lang="ru">Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO, ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019;40:87_165.</mixed-citation><mixed-citation xml:lang="en">Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO, ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019;40:87_165.</mixed-citation></citation-alternatives></ref><ref id="cit201"><label>201</label><citation-alternatives><mixed-citation xml:lang="ru">Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, Ree M, Shah AI, Burchette RJ. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008;300:1038_1046.</mixed-citation><mixed-citation xml:lang="en">Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, Ree M, Shah AI, Burchette RJ. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008;300:1038_1046.</mixed-citation></citation-alternatives></ref><ref id="cit202"><label>202</label><citation-alternatives><mixed-citation xml:lang="ru">Giacoppo D, Gargiulo G, Buccheri S, Aruta P, Byrne RA, Cassese S, Dangas G, Kastrati A, Mehran R, Tamburino C, Capodanno D. Preventive strategies for contrast-induced acute kidney injury in patients undergoing percutaneous coronary procedures: evidence from a hierarchical Bayesian network metaanalysis of 124 trials and 28 240 patients. Circ Cardiovasc Interv 2017;10:e004383.</mixed-citation><mixed-citation xml:lang="en">Giacoppo D, Gargiulo G, Buccheri S, Aruta P, Byrne RA, Cassese S, Dangas G, Kastrati A, Mehran R, Tamburino C, Capodanno D. Preventive strategies for contrast-induced acute kidney injury in patients undergoing percutaneous coronary procedures: evidence from a hierarchical Bayesian network metaanalysis of 124 trials and 28 240 patients. Circ Cardiovasc Interv 2017;10:e004383.</mixed-citation></citation-alternatives></ref><ref id="cit203"><label>203</label><citation-alternatives><mixed-citation xml:lang="ru">Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, Ommen VV, Wildberger JE. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet 2017;389:1312_1322.</mixed-citation><mixed-citation xml:lang="en">Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, Ommen VV, Wildberger JE. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet 2017;389:1312_1322.</mixed-citation></citation-alternatives></ref><ref id="cit204"><label>204</label><citation-alternatives><mixed-citation xml:lang="ru">Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin SS, Conner TA, Chertow GM, Bhatt DL, Shunk K, Parikh CR, McFalls EO, Brophy M, Ferguson R, Wu H, Androsenko M, Myles J, Kaufman J, Palevsky PM, PRESERVE Trial Group. Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med 2018;378:603_614.</mixed-citation><mixed-citation xml:lang="en">Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin SS, Conner TA, Chertow GM, Bhatt DL, Shunk K, Parikh CR, McFalls EO, Brophy M, Ferguson R, Wu H, Androsenko M, Myles J, Kaufman J, Palevsky PM, PRESERVE Trial Group. Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med 2018;378:603_614.</mixed-citation></citation-alternatives></ref><ref id="cit205"><label>205</label><citation-alternatives><mixed-citation xml:lang="ru">Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO, ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87-165.</mixed-citation><mixed-citation xml:lang="en">Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO, ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87-165.</mixed-citation></citation-alternatives></ref><ref id="cit206"><label>206</label><citation-alternatives><mixed-citation xml:lang="ru">Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, Ree M, Shah AI, Burchette RJ. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008;300:1038_1046.</mixed-citation><mixed-citation xml:lang="en">Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, Ree M, Shah AI, Burchette RJ. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008;300:1038_1046.</mixed-citation></citation-alternatives></ref><ref id="cit207"><label>207</label><citation-alternatives><mixed-citation xml:lang="ru">Brar SS, Aharonian V, Mansukhani P, Moore N, Shen AY, Jorgensen M, Dua A, Short L, Kane K. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet 2014;383:1814_1823.</mixed-citation><mixed-citation xml:lang="en">Brar SS, Aharonian V, Mansukhani P, Moore N, Shen AY, Jorgensen M, Dua A, Short L, Kane K. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet 2014;383:1814_1823.</mixed-citation></citation-alternatives></ref><ref id="cit208"><label>208</label><citation-alternatives><mixed-citation xml:lang="ru">Reiter M, Twerenbold R, Reichlin T, Haaf P, Peter F, Meissner J, Hochholzer W, Stelzig C, Freese M, Heinisch C, Breidthardt T, Freidank H, Winkler K, Campodarve I, Gea J, Mueller C. Early diagnosis of acute myocardial infarction in the elderly using more sensitive cardiac troponin assays. Eur Heart J 2011;32:1379_1389.</mixed-citation><mixed-citation xml:lang="en">Reiter M, Twerenbold R, Reichlin T, Haaf P, Peter F, Meissner J, Hochholzer W, Stelzig C, Freese M, Heinisch C, Breidthardt T, Freidank H, Winkler K, Campodarve I, Gea J, Mueller C. Early diagnosis of acute myocardial infarction in the elderly using more sensitive cardiac troponin assays. Eur Heart J 2011;32:1379_1389.</mixed-citation></citation-alternatives></ref><ref id="cit209"><label>209</label><citation-alternatives><mixed-citation xml:lang="ru">Bach RG, Cannon CP, Weintraub WS, DiBattiste PM, Demopoulos LA, Anderson HV, DeLucca PT, Mahoney EM, Murphy SA, Braunwald E. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med 2004;141:186_195.</mixed-citation><mixed-citation xml:lang="en">Bach RG, Cannon CP, Weintraub WS, DiBattiste PM, Demopoulos LA, Anderson HV, DeLucca PT, Mahoney EM, Murphy SA, Braunwald E. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med 2004;141:186_195.</mixed-citation></citation-alternatives></ref><ref id="cit210"><label>210</label><citation-alternatives><mixed-citation xml:lang="ru">Damman P, Clayton T, Wallentin L, Lagerqvist B, Fox KA, Hirsch A, Windhausen F, Swahn E, Pocock SJ, Tijssen JG, de Winter RJ. Effects of age on long-term outcomes after a routine invasive or selective invasive strategy in patients presenting with non-ST segment elevation acute coronary syndromes: a collaborative analysis of individual data from the FRISC II - ICTUS - RITA-3 (FIR) trials. Heart 2012;98:207_213.</mixed-citation><mixed-citation xml:lang="en">Damman P, Clayton T, Wallentin L, Lagerqvist B, Fox KA, Hirsch A, Windhausen F, Swahn E, Pocock SJ, Tijssen JG, de Winter RJ. Effects of age on long-term outcomes after a routine invasive or selective invasive strategy in patients presenting with non-ST segment elevation acute coronary syndromes: a collaborative analysis of individual data from the FRISC II - ICTUS - RITA-3 (FIR) trials. Heart 2012;98:207_213.</mixed-citation></citation-alternatives></ref><ref id="cit211"><label>211</label><citation-alternatives><mixed-citation xml:lang="ru">Rosengren A, Wallentin L, Simoons M, Gitt AK, Behar S, Battler A, Hasdai D. Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey. Eur Heart J 2006; 27: 789-795.</mixed-citation><mixed-citation xml:lang="en">Rosengren A, Wallentin L, Simoons M, Gitt AK, Behar S, Battler A, Hasdai D. Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey. Eur Heart J 2006; 27: 789-795.</mixed-citation></citation-alternatives></ref><ref id="cit212"><label>212</label><citation-alternatives><mixed-citation xml:lang="ru">Bauer T, Koeth O, Junger C, Heer T, Wienbergen H, Gitt A, Zahn R, Senges J, Zeymer U, Acute Coronary Syndromes Registry (ACOS) Investigators. Effect of an invasive strategy on in-hospital outcome in elderly patients with non-STelevation myocardial infarction. Eur Heart J 2007; 28: 2873-2878.</mixed-citation><mixed-citation xml:lang="en">Bauer T, Koeth O, Junger C, Heer T, Wienbergen H, Gitt A, Zahn R, Senges J, Zeymer U, Acute Coronary Syndromes Registry (ACOS) Investigators. Effect of an invasive strategy on in-hospital outcome in elderly patients with non-STelevation myocardial infarction. Eur Heart J 2007; 28: 2873-2878.</mixed-citation></citation-alternatives></ref><ref id="cit213"><label>213</label><citation-alternatives><mixed-citation xml:lang="ru">Bach RG, Cannon CP, Weintraub WS, DiBattiste PM, Demopoulos LA, Anderson HV, DeLucca PT, Mahoney EM, Murphy SA, Braunwald E. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med 2004; 141: 186-195.</mixed-citation><mixed-citation xml:lang="en">Bach RG, Cannon CP, Weintraub WS, DiBattiste PM, Demopoulos LA, Anderson HV, DeLucca PT, Mahoney EM, Murphy SA, Braunwald E. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med 2004; 141: 186-195.</mixed-citation></citation-alternatives></ref><ref id="cit214"><label>214</label><citation-alternatives><mixed-citation xml:lang="ru">Tegn N, Abdelnoor M, Aaberge L, Endresen K, Smith P, Aakhus S, Gjertsen E, Dahl-Hofseth O, Ranhoff AH, Gullestad L, Bendz B, After Eighty study investigators. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet 2016; 387: 1057-1065.</mixed-citation><mixed-citation xml:lang="en">Tegn N, Abdelnoor M, Aaberge L, Endresen K, Smith P, Aakhus S, Gjertsen E, Dahl-Hofseth O, Ranhoff AH, Gullestad L, Bendz B, After Eighty study investigators. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet 2016; 387: 1057-1065.</mixed-citation></citation-alternatives></ref><ref id="cit215"><label>215</label><citation-alternatives><mixed-citation xml:lang="ru">Skolnick AH, Alexander KP, Chen AY, Roe MT, Pollack CV, Jr., Ohman EM, Rumsfeld JS, Gibler WB, Peterson ED, Cohen DJ. Characteristics, management, and outcomes of 5,557 patients age &gt; or =90 years with acute coronary syndromes: results from the CRUSADE Initiative. JACC 2007; 49: 1790-1797.</mixed-citation><mixed-citation xml:lang="en">Skolnick AH, Alexander KP, Chen AY, Roe MT, Pollack CV, Jr., Ohman EM, Rumsfeld JS, Gibler WB, Peterson ED, Cohen DJ. Characteristics, management, and outcomes of 5,557 patients age &gt; or =90 years with acute coronary syndromes: results from the CRUSADE Initiative. JACC 2007; 49: 1790-1797.</mixed-citation></citation-alternatives></ref><ref id="cit216"><label>216</label><citation-alternatives><mixed-citation xml:lang="ru">Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM, American Heart Association Council on Clinical Cardiology, Society of Geriatric Cardiology. Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on clinical cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007;115:2549_2569.</mixed-citation><mixed-citation xml:lang="en">Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM, American Heart Association Council on Clinical Cardiology, Society of Geriatric Cardiology. Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on clinical cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007;115:2549_2569.</mixed-citation></citation-alternatives></ref><ref id="cit217"><label>217</label><citation-alternatives><mixed-citation xml:lang="ru">Alberg A., Berstrand R., Jonasson S. et al. Cessation of smoking after myocardial infarction. Effects on mortality after 10 years. Br. Heart. J. 1983;49:416–422.</mixed-citation><mixed-citation xml:lang="en">Alberg A., Berstrand R., Jonasson S. et al. Cessation of smoking after myocardial infarction. Effects on mortality after 10 years. Br. Heart. J. 1983;49:416–422.</mixed-citation></citation-alternatives></ref><ref id="cit218"><label>218</label><citation-alternatives><mixed-citation xml:lang="ru">McRobbie H, Bullen C, Hartmann-Boyce J, Hajek P. Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev 2014;12:CD010216.</mixed-citation><mixed-citation xml:lang="en">McRobbie H, Bullen C, Hartmann-Boyce J, Hajek P. Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev 2014;12:CD010216.</mixed-citation></citation-alternatives></ref><ref id="cit219"><label>219</label><citation-alternatives><mixed-citation xml:lang="ru">Meine T.J., Richard P. et al. Reduced incidence of admissions for myocardial infarction associated with public smoking ban: before and after study. BMJ 2004;328:977–980.</mixed-citation><mixed-citation xml:lang="en">Meine T.J., Richard P. et al. Reduced incidence of admissions for myocardial infarction associated with public smoking ban: before and after study. BMJ 2004;328:977–980.</mixed-citation></citation-alternatives></ref><ref id="cit220"><label>220</label><citation-alternatives><mixed-citation xml:lang="ru">Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010;121:750_758.</mixed-citation><mixed-citation xml:lang="en">Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010;121:750_758.</mixed-citation></citation-alternatives></ref><ref id="cit221"><label>221</label><citation-alternatives><mixed-citation xml:lang="ru">Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003;290:86_97.</mixed-citation><mixed-citation xml:lang="en">Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003;290:86_97.</mixed-citation></citation-alternatives></ref><ref id="cit222"><label>222</label><citation-alternatives><mixed-citation xml:lang="ru">Hackshaw A, Morris JK, Boniface S, Tang JL, Milenkovic D. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ 2018; 360: j5855.</mixed-citation><mixed-citation xml:lang="en">Hackshaw A, Morris JK, Boniface S, Tang JL, Milenkovic D. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ 2018; 360: j5855.</mixed-citation></citation-alternatives></ref><ref id="cit223"><label>223</label><citation-alternatives><mixed-citation xml:lang="ru">Kotseva K, Wood D, De Bacquer D, De Backer G, Ryden L, Jennings C, Gyberg V, Amouyel P, Bruthans J, Castro Conde A, Cifkova R, Deckers JW, De Sutter J, Dilic M, Dolzhenko M, Erglis A, Fras Z, Gaita D, Gotcheva N, Goudevenos J, Heuschmann P, Laucevicius A, Lehto S, Lovic D, Milicic D, Moore D, Nicolaides E, Oganov R, Pajak A, Pogosova N, Reiner Z, Stagmo M, Stork S, Tokgozoglu L, Vulic D, EUROASPIRE Investigators. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23: 636-648.</mixed-citation><mixed-citation xml:lang="en">Kotseva K, Wood D, De Bacquer D, De Backer G, Ryden L, Jennings C, Gyberg V, Amouyel P, Bruthans J, Castro Conde A, Cifkova R, Deckers JW, De Sutter J, Dilic M, Dolzhenko M, Erglis A, Fras Z, Gaita D, Gotcheva N, Goudevenos J, Heuschmann P, Laucevicius A, Lehto S, Lovic D, Milicic D, Moore D, Nicolaides E, Oganov R, Pajak A, Pogosova N, Reiner Z, Stagmo M, Stork S, Tokgozoglu L, Vulic D, EUROASPIRE Investigators. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23: 636-648.</mixed-citation></citation-alternatives></ref><ref id="cit224"><label>224</label><citation-alternatives><mixed-citation xml:lang="ru">Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S, ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315-2381.</mixed-citation><mixed-citation xml:lang="en">Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S, ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315-2381.</mixed-citation></citation-alternatives></ref><ref id="cit225"><label>225</label><citation-alternatives><mixed-citation xml:lang="ru">Freeman AM, Morris PB, Barnard N, Esselstyn CB, Ros E, Agatston A, Devries S, O’Keefe J, Miller M, Ornish D, Williams K, Kris-Etherton P. Trending cardiovascular nutrition controversies. J Am Coll Cardiol 2017; 69:1 172-1187.</mixed-citation><mixed-citation xml:lang="en">Freeman AM, Morris PB, Barnard N, Esselstyn CB, Ros E, Agatston A, Devries S, O’Keefe J, Miller M, Ornish D, Williams K, Kris-Etherton P. Trending cardiovascular nutrition controversies. J Am Coll Cardiol 2017; 69:1 172-1187.</mixed-citation></citation-alternatives></ref><ref id="cit226"><label>226</label><citation-alternatives><mixed-citation xml:lang="ru">Miller V, Mente A, Dehghan M, Rangarajan S, Zhang X, Swaminathan S, Dagenais G, Gupta R, Mohan V, Lear S, Bangdiwala SI, Schutte AE, WentzelViljoen E, Avezum A, Altuntas Y, Yusoff K, Ismail N, Peer N, Chifamba J, Diaz R, Rahman O, Mohammadifard N, Lana F, Zatonska K, Wielgosz A, Yusufali A, Iqbal R, Lopez-Jaramillo P, Khatib R, Rosengren A, Kutty VR, Li W, Liu J, Liu X, Yin L, Teo K, Anand S, Yusuf S, Prospective Urban Rural Epidemiology study investigators. Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study. Lancet 2017;390:2037-2049.</mixed-citation><mixed-citation xml:lang="en">Miller V, Mente A, Dehghan M, Rangarajan S, Zhang X, Swaminathan S, Dagenais G, Gupta R, Mohan V, Lear S, Bangdiwala SI, Schutte AE, WentzelViljoen E, Avezum A, Altuntas Y, Yusoff K, Ismail N, Peer N, Chifamba J, Diaz R, Rahman O, Mohammadifard N, Lana F, Zatonska K, Wielgosz A, Yusufali A, Iqbal R, Lopez-Jaramillo P, Khatib R, Rosengren A, Kutty VR, Li W, Liu J, Liu X, Yin L, Teo K, Anand S, Yusuf S, Prospective Urban Rural Epidemiology study investigators. Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study. Lancet 2017;390:2037-2049.</mixed-citation></citation-alternatives></ref><ref id="cit227"><label>227</label><citation-alternatives><mixed-citation xml:lang="ru">Piano MR. Alcohol’s effects on the cardiovascular system. Alcohol Res 2017;38:219-241.</mixed-citation><mixed-citation xml:lang="en">Piano MR. Alcohol’s effects on the cardiovascular system. Alcohol Res 2017;38:219-241.</mixed-citation></citation-alternatives></ref><ref id="cit228"><label>228</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.</mixed-citation><mixed-citation xml:lang="en">Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.</mixed-citation></citation-alternatives></ref><ref id="cit229"><label>229</label><citation-alternatives><mixed-citation xml:lang="ru">Booth JN, 3rd, Levitan EB, Brown TM, Farkouh ME, Safford MM, Muntner P. Effect of sustaining lifestyle modifications (nonsmoking, weight reduction, physical activity, and mediterranean diet) after healing of myocardial infarction, percutaneous intervention, or coronary bypass (from the Reasons for Geographic and Racial Differences in Stroke Study). Am J Cardiol 2014;113:1933_1940.</mixed-citation><mixed-citation xml:lang="en">Booth JN, 3rd, Levitan EB, Brown TM, Farkouh ME, Safford MM, Muntner P. Effect of sustaining lifestyle modifications (nonsmoking, weight reduction, physical activity, and mediterranean diet) after healing of myocardial infarction, percutaneous intervention, or coronary bypass (from the Reasons for Geographic and Racial Differences in Stroke Study). Am J Cardiol 2014;113:1933_1940.</mixed-citation></citation-alternatives></ref><ref id="cit230"><label>230</label><citation-alternatives><mixed-citation xml:lang="ru">Giannuzzi P, Temporelli PL, Marchioli R, Maggioni AP, Balestroni G, Ceci V, Chieffo C, Gattone M, Griffo R, Schweiger C, Tavazzi L, Urbinati S, Valagussa F, Vanuzzo D, GOSPEL Investigators. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network. Arch Intern Med 2008;168:2194_2204.</mixed-citation><mixed-citation xml:lang="en">Giannuzzi P, Temporelli PL, Marchioli R, Maggioni AP, Balestroni G, Ceci V, Chieffo C, Gattone M, Griffo R, Schweiger C, Tavazzi L, Urbinati S, Valagussa F, Vanuzzo D, GOSPEL Investigators. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network. Arch Intern Med 2008;168:2194_2204.</mixed-citation></citation-alternatives></ref><ref id="cit231"><label>231</label><citation-alternatives><mixed-citation xml:lang="ru">Trichopoulou A, Bamia C, Norat T, Overvad K, Schmidt EB, Tjønneland A, Halkjaer J, Clavel-Chapelon F, Vercambre MN, Boutron-Ruault MC, Linseisen J, Rohrmann S, Boeing H, Weikert C, Benetou V, Psaltopoulou T, Orfanos P, Boffetta P, Masala G, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Ocke MC, Peeters PH, Van der Schouw YT, González C, Sanchez MJ, Chirlaque MD, Moreno C, Larrañaga N, Van Guelpen B, Jansson JH, Bingham S, Khaw KT, Spencer EA, Key T, Riboli E, Trichopoulos D. Modified Mediterranean diet and survival after myocardial infarction: the EPIC-Elderly Study. Eur. J. Epidemiol. 2007;22:871–881.</mixed-citation><mixed-citation xml:lang="en">Trichopoulou A, Bamia C, Norat T, Overvad K, Schmidt EB, Tjønneland A, Halkjaer J, Clavel-Chapelon F, Vercambre MN, Boutron-Ruault MC, Linseisen J, Rohrmann S, Boeing H, Weikert C, Benetou V, Psaltopoulou T, Orfanos P, Boffetta P, Masala G, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Ocke MC, Peeters PH, Van der Schouw YT, González C, Sanchez MJ, Chirlaque MD, Moreno C, Larrañaga N, Van Guelpen B, Jansson JH, Bingham S, Khaw KT, Spencer EA, Key T, Riboli E, Trichopoulos D. Modified Mediterranean diet and survival after myocardial infarction: the EPIC-Elderly Study. Eur. J. Epidemiol. 2007;22:871–881.</mixed-citation></citation-alternatives></ref><ref id="cit232"><label>232</label><citation-alternatives><mixed-citation xml:lang="ru">Dalen JE, Devries S. Diets to prevent coronary heart disease 1957-2013: what have we learned?Am. J. Med. 2014;127:364-369.</mixed-citation><mixed-citation xml:lang="en">Dalen JE, Devries S. Diets to prevent coronary heart disease 1957-2013: what have we learned?Am. J. Med. 2014;127:364-369.</mixed-citation></citation-alternatives></ref><ref id="cit233"><label>233</label><citation-alternatives><mixed-citation xml:lang="ru">Luo C, Zhang Y, Ding Y, Shan Z, Chen S, Yu M, Hu FB, Liu L. Nut consumption and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis. Am. J. Clin. Nutr.2014;100:256-269.</mixed-citation><mixed-citation xml:lang="en">Luo C, Zhang Y, Ding Y, Shan Z, Chen S, Yu M, Hu FB, Liu L. Nut consumption and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis. Am. J. Clin. Nutr.2014;100:256-269.</mixed-citation></citation-alternatives></ref><ref id="cit234"><label>234</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng J, Huang T, Yu Y, Hu X, Yang B, Li D. Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. Public Health Nutr. 2012;15:725-737.</mixed-citation><mixed-citation xml:lang="en">Zheng J, Huang T, Yu Y, Hu X, Yang B, Li D. Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. Public Health Nutr. 2012;15:725-737.</mixed-citation></citation-alternatives></ref><ref id="cit235"><label>235</label><citation-alternatives><mixed-citation xml:lang="ru">Wang X, Ouyang Y, Liu J, Zhu M, Zhao G, Bao W, Hu FB. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. BMJ 2014;349:4490.</mixed-citation><mixed-citation xml:lang="en">Wang X, Ouyang Y, Liu J, Zhu M, Zhao G, Bao W, Hu FB. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. BMJ 2014;349:4490.</mixed-citation></citation-alternatives></ref><ref id="cit236"><label>236</label><citation-alternatives><mixed-citation xml:lang="ru">de Lorgeril M, Salen P, Martin JL, Boucher F, Paillard F, de Leiris J. Wine drinking and risks of cardiovascular complications after recent acute myocardial infarction. Circulation 2002;106:1465–1469.</mixed-citation><mixed-citation xml:lang="en">de Lorgeril M, Salen P, Martin JL, Boucher F, Paillard F, de Leiris J. Wine drinking and risks of cardiovascular complications after recent acute myocardial infarction. Circulation 2002;106:1465–1469.</mixed-citation></citation-alternatives></ref><ref id="cit237"><label>237</label><citation-alternatives><mixed-citation xml:lang="ru">Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju ShN, Wormser D, Gao P, Kaptoge S, Berrington de Gonzalez A, Cairns BJ, Huxley R, Jackson ChL, Joshy G, Lewington S, Manson JE, Murphy N, Patel AV, Samet JM, Woodward M, Zheng W, Zhou M, Bansal N, Barricarte A, Carter B, Cerhan JR, Smith GD, Fang X, Franco OH, Green J, Halsey J, Hildebrand JS, Jung KJ, Korda RJ, McLerran DF, Moore SC, O’Keeffe LM, Paige E, Ramond A, Reeves GK, Rolland B, Sacerdote C, Sattar N, Sofianopoulou E, Stevens J, Thun M, Ueshima H, Yang L, Yun YD, Willeit P, Banks E, Beral V, Chen Zh, Gapstur SM, Gunter MJ, Hartge P, Jee SH, Lam TH, Peto R, Potter JD, Willett WC, Thompson SG, Danesh J, Hu FB. Body-mass index and allcause mortality: individual participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016;388(10046):776–786.</mixed-citation><mixed-citation xml:lang="en">Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju ShN, Wormser D, Gao P, Kaptoge S, Berrington de Gonzalez A, Cairns BJ, Huxley R, Jackson ChL, Joshy G, Lewington S, Manson JE, Murphy N, Patel AV, Samet JM, Woodward M, Zheng W, Zhou M, Bansal N, Barricarte A, Carter B, Cerhan JR, Smith GD, Fang X, Franco OH, Green J, Halsey J, Hildebrand JS, Jung KJ, Korda RJ, McLerran DF, Moore SC, O’Keeffe LM, Paige E, Ramond A, Reeves GK, Rolland B, Sacerdote C, Sattar N, Sofianopoulou E, Stevens J, Thun M, Ueshima H, Yang L, Yun YD, Willeit P, Banks E, Beral V, Chen Zh, Gapstur SM, Gunter MJ, Hartge P, Jee SH, Lam TH, Peto R, Potter JD, Willett WC, Thompson SG, Danesh J, Hu FB. Body-mass index and allcause mortality: individual participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016;388(10046):776–786.</mixed-citation></citation-alternatives></ref><ref id="cit238"><label>238</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2016:CD001800.</mixed-citation><mixed-citation xml:lang="en">Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2016:CD001800.</mixed-citation></citation-alternatives></ref><ref id="cit239"><label>239</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng W, Zhang Z, Cheng W, Yang C, Diao L, Liu W. Associations of leisuretime physical activity with cardiovascular mortality: A systematic review and metaanalysis of 44 prospective cohort studies. Eur J Prev Cardiol 2018;25:1864_1872.</mixed-citation><mixed-citation xml:lang="en">Cheng W, Zhang Z, Cheng W, Yang C, Diao L, Liu W. Associations of leisuretime physical activity with cardiovascular mortality: A systematic review and metaanalysis of 44 prospective cohort studies. Eur J Prev Cardiol 2018;25:1864_1872.</mixed-citation></citation-alternatives></ref><ref id="cit240"><label>240</label><citation-alternatives><mixed-citation xml:lang="ru">Keteyian SJ, Brawner CA, Savage PD, Ehrman JK, Schairer J, Divine G, Aldred H, Ophaug K, Ades PA. Peak aerobic capacity predicts prognosis in patients with coronary heart disease. Am Heart J 2008;156:292_300.</mixed-citation><mixed-citation xml:lang="en">Keteyian SJ, Brawner CA, Savage PD, Ehrman JK, Schairer J, Divine G, Aldred H, Ophaug K, Ades PA. Peak aerobic capacity predicts prognosis in patients with coronary heart disease. Am Heart J 2008;156:292_300.</mixed-citation></citation-alternatives></ref><ref id="cit241"><label>241</label><citation-alternatives><mixed-citation xml:lang="ru">Lahtinen M, Toukola T, Junttila MJ, Piira OP, Lepojarvi S, Kaariainen M, Huikuri HV, Tulppo MP, Kiviniemi AM. Effect of changes in physical activity on risk for cardiac death in patients with coronary artery disease. Am J Cardiol 2018;121:143_148.</mixed-citation><mixed-citation xml:lang="en">Lahtinen M, Toukola T, Junttila MJ, Piira OP, Lepojarvi S, Kaariainen M, Huikuri HV, Tulppo MP, Kiviniemi AM. Effect of changes in physical activity on risk for cardiac death in patients with coronary artery disease. Am J Cardiol 2018;121:143_148.</mixed-citation></citation-alternatives></ref><ref id="cit242"><label>242</label><citation-alternatives><mixed-citation xml:lang="ru">Benzer W, Rauch B, Schmid JP, Zwisler AD, Dendale P, Davos CH, Kouidi E, Simon A, Abreu A, Pogosova N, Gaita D, Miletic B, Bonner G, Ouarrak T, McGee H, EuroCaReD study group. Exercise-based cardiac rehabilitation in twelve European countries results of the European cardiac rehabilitation registry. Int J Cardiol 2017;228:58_67.</mixed-citation><mixed-citation xml:lang="en">Benzer W, Rauch B, Schmid JP, Zwisler AD, Dendale P, Davos CH, Kouidi E, Simon A, Abreu A, Pogosova N, Gaita D, Miletic B, Bonner G, Ouarrak T, McGee H, EuroCaReD study group. Exercise-based cardiac rehabilitation in twelve European countries results of the European cardiac rehabilitation registry. Int J Cardiol 2017;228:58_67.</mixed-citation></citation-alternatives></ref><ref id="cit243"><label>243</label><citation-alternatives><mixed-citation xml:lang="ru">Stewart RAH, Held C, Hadziosmanovic N, Armstrong PW, Cannon CP, Granger CB, Hagstrom E, Hochman JS, Koenig W, Lonn E, Nicolau JC, Steg PG, Vedin O, Wallentin L, White HD, Investigators STABILITY. Physical activity and mortality in patients with stable coronary heart disease. J Am Coll Cardiol 2017;70:1689_1700.</mixed-citation><mixed-citation xml:lang="en">Stewart RAH, Held C, Hadziosmanovic N, Armstrong PW, Cannon CP, Granger CB, Hagstrom E, Hochman JS, Koenig W, Lonn E, Nicolau JC, Steg PG, Vedin O, Wallentin L, White HD, Investigators STABILITY. Physical activity and mortality in patients with stable coronary heart disease. J Am Coll Cardiol 2017;70:1689_1700.</mixed-citation></citation-alternatives></ref><ref id="cit244"><label>244</label><citation-alternatives><mixed-citation xml:lang="ru">de Vries H, Kemps HM, van Engen-Verheul MM, Kraaijenhagen RA, Peek N. Cardiac rehabilitation and survival in a large representative community cohort of Dutch patients. Eur Heart J 2015;36:1519_1528.</mixed-citation><mixed-citation xml:lang="en">de Vries H, Kemps HM, van Engen-Verheul MM, Kraaijenhagen RA, Peek N. Cardiac rehabilitation and survival in a large representative community cohort of Dutch patients. Eur Heart J 2015;36:1519_1528.</mixed-citation></citation-alternatives></ref><ref id="cit245"><label>245</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2016:CD001800.</mixed-citation><mixed-citation xml:lang="en">Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2016:CD001800.</mixed-citation></citation-alternatives></ref><ref id="cit246"><label>246</label><citation-alternatives><mixed-citation xml:lang="ru">Rauch B, Davos CH, Doherty P, Saure D, Metzendorf MI, Salzwedel A, Voller H, Jensen K, Schmid JP, ‘Cardiac Rehabilitation Section’, European Association of Preventive Cardiology (EAPC), in cooperation with the Institute of Medical Biometry and Informatics (IMBI), Department of Medical Biometry, University of Heidelberg, and the Cochrane Metabolic and Endocrine Disorders Group, Institute of General Practice, HeinrichHeine University, Dusseldorf, Germany. The prognostic effect of cardiac rehabilitation in the era of acute revascularization and statin therapy: a systematic review and meta-analysis of randomized and non-randomized studies – The Cardiac Rehabilitation Outcome Study (CROS). Eur J Prev Cardiol 2016;23:1914_1939.</mixed-citation><mixed-citation xml:lang="en">Rauch B, Davos CH, Doherty P, Saure D, Metzendorf MI, Salzwedel A, Voller H, Jensen K, Schmid JP, ‘Cardiac Rehabilitation Section’, European Association of Preventive Cardiology (EAPC), in cooperation with the Institute of Medical Biometry and Informatics (IMBI), Department of Medical Biometry, University of Heidelberg, and the Cochrane Metabolic and Endocrine Disorders Group, Institute of General Practice, HeinrichHeine University, Dusseldorf, Germany. The prognostic effect of cardiac rehabilitation in the era of acute revascularization and statin therapy: a systematic review and meta-analysis of randomized and non-randomized studies – The Cardiac Rehabilitation Outcome Study (CROS). Eur J Prev Cardiol 2016;23:1914_1939.</mixed-citation></citation-alternatives></ref><ref id="cit247"><label>247</label><citation-alternatives><mixed-citation xml:lang="ru">Vanhees L, De Sutter J, Gelada SN, Doyle F, Prescott E, Cornelissen V, Kouidi E, Dugmore D, Vanuzzo D, Borjesson M, Doherty P, EACPR. Importance of characteristics and modalities of physical activity and exercise in defining the benefits to cardiovascular health within the general population: recommendations from the EACPR (Part I). Eur J Prev Cardiol 2012;19:670-686.</mixed-citation><mixed-citation xml:lang="en">Vanhees L, De Sutter J, Gelada SN, Doyle F, Prescott E, Cornelissen V, Kouidi E, Dugmore D, Vanuzzo D, Borjesson M, Doherty P, EACPR. Importance of characteristics and modalities of physical activity and exercise in defining the benefits to cardiovascular health within the general population: recommendations from the EACPR (Part I). Eur J Prev Cardiol 2012;19:670-686.</mixed-citation></citation-alternatives></ref><ref id="cit248"><label>248</label><citation-alternatives><mixed-citation xml:lang="ru">Vanhees L, Geladas N, Hansen D, Kouidi E, Niebauer J, Reiner Z, Cornelissen V, Adamopoulos S, Prescott E, Borjesson M, BjarnasonWehrens B, Bjornstad HH, Cohen-Solal A, Conraads V, Corrado D, De Sutter J, Doherty P, Doyle F, Dugmore D, Ellingsen O, Fagard R, Giada F, Gielen S, Hager A, Halle M, Heidbuchel H, Jegier A, Mazic S, McGee H, Mellwig KP, Mendes M, Mezzani A, Pattyn N, Pelliccia A, Piepoli M, Rauch B, Schmidt-Trucksass A, Takken T, van Buuren F, Vanuzzo D. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II. Eur J Prev Cardiol 2012;19:1005-1033.</mixed-citation><mixed-citation xml:lang="en">Vanhees L, Geladas N, Hansen D, Kouidi E, Niebauer J, Reiner Z, Cornelissen V, Adamopoulos S, Prescott E, Borjesson M, BjarnasonWehrens B, Bjornstad HH, Cohen-Solal A, Conraads V, Corrado D, De Sutter J, Doherty P, Doyle F, Dugmore D, Ellingsen O, Fagard R, Giada F, Gielen S, Hager A, Halle M, Heidbuchel H, Jegier A, Mazic S, McGee H, Mellwig KP, Mendes M, Mezzani A, Pattyn N, Pelliccia A, Piepoli M, Rauch B, Schmidt-Trucksass A, Takken T, van Buuren F, Vanuzzo D. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II. Eur J Prev Cardiol 2012;19:1005-1033.</mixed-citation></citation-alternatives></ref><ref id="cit249"><label>249</label><citation-alternatives><mixed-citation xml:lang="ru">Vanhees L, Rauch B, Piepoli M, van Buuren F, Takken T, Borjesson M, Bjarnason-Wehrens B, Doherty P, Dugmore D, Halle M, Writing Group, EACPR. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular disease (Part III). Eur J Prev Cardiol 2012; 19: 1333-1356.</mixed-citation><mixed-citation xml:lang="en">Vanhees L, Rauch B, Piepoli M, van Buuren F, Takken T, Borjesson M, Bjarnason-Wehrens B, Doherty P, Dugmore D, Halle M, Writing Group, EACPR. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular disease (Part III). Eur J Prev Cardiol 2012; 19: 1333-1356.</mixed-citation></citation-alternatives></ref><ref id="cit250"><label>250</label><citation-alternatives><mixed-citation xml:lang="ru">Lahtinen M, Toukola T, Junttila MJ, Piira OP, Lepojarvi S, Kaariainen M, Huikuri HV, Tulppo MP, Kiviniemi AM. Effect of changes in physical activity on risk for cardiac death in patients with coronary artery disease. Am J Cardiol 2018;121:143-148.</mixed-citation><mixed-citation xml:lang="en">Lahtinen M, Toukola T, Junttila MJ, Piira OP, Lepojarvi S, Kaariainen M, Huikuri HV, Tulppo MP, Kiviniemi AM. Effect of changes in physical activity on risk for cardiac death in patients with coronary artery disease. Am J Cardiol 2018;121:143-148.</mixed-citation></citation-alternatives></ref><ref id="cit251"><label>251</label><citation-alternatives><mixed-citation xml:lang="ru">Voogdt-Pruis HR, Beusmans GH, Gorgels AP, Kester AD, Van Ree JW. Effectiveness of nurse-delivered cardiovascular risk management in primarycare: a randomised trial. Br J Gen Pract 2010;60:40_46.</mixed-citation><mixed-citation xml:lang="en">Voogdt-Pruis HR, Beusmans GH, Gorgels AP, Kester AD, Van Ree JW. Effectiveness of nurse-delivered cardiovascular risk management in primarycare: a randomised trial. Br J Gen Pract 2010;60:40_46.</mixed-citation></citation-alternatives></ref><ref id="cit252"><label>252</label><citation-alternatives><mixed-citation xml:lang="ru">Wood DA, Kotseva K, Connolly S, Jennings C, Mead A, Jones J, Holden A, De Bacquer D, Collier T, De Backer G, Faergeman O, EUROACTION Study Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008;371:1999-2012.</mixed-citation><mixed-citation xml:lang="en">Wood DA, Kotseva K, Connolly S, Jennings C, Mead A, Jones J, Holden A, De Bacquer D, Collier T, De Backer G, Faergeman O, EUROACTION Study Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008;371:1999-2012.</mixed-citation></citation-alternatives></ref><ref id="cit253"><label>253</label><citation-alternatives><mixed-citation xml:lang="ru">Rauch B, Davos CH, Doherty P, Saure D, Metzendorf MI, Salzwedel A, Voller H, Jensen K, Schmid JP, ‘Cardiac Rehabilitation Section’, European Association of Preventive Cardiology (EAPC), in cooperation with the Institute of Medical Biometry and Informatics (IMBI), Department of Medical Biometry, University of Heidelberg, and the Cochrane Metabolic and Endocrine Disorders Group, Institute of General Practice, Heinrich-Heine University, Du¨sseldorf, Germany. The prognostic effect of cardiac rehabilitation in the era of acute revascularization and statin therapy: a systematic review and meta-analysis of randomized and non-randomized studies – The Cardiac Rehabilitation Outcome Study (CROS). Eur J Prev Cardiol 2016;23:1914-1939.</mixed-citation><mixed-citation xml:lang="en">Rauch B, Davos CH, Doherty P, Saure D, Metzendorf MI, Salzwedel A, Voller H, Jensen K, Schmid JP, ‘Cardiac Rehabilitation Section’, European Association of Preventive Cardiology (EAPC), in cooperation with the Institute of Medical Biometry and Informatics (IMBI), Department of Medical Biometry, University of Heidelberg, and the Cochrane Metabolic and Endocrine Disorders Group, Institute of General Practice, Heinrich-Heine University, Du¨sseldorf, Germany. The prognostic effect of cardiac rehabilitation in the era of acute revascularization and statin therapy: a systematic review and meta-analysis of randomized and non-randomized studies – The Cardiac Rehabilitation Outcome Study (CROS). Eur J Prev Cardiol 2016;23:1914-1939.</mixed-citation></citation-alternatives></ref><ref id="cit254"><label>254</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2016:CD001800.</mixed-citation><mixed-citation xml:lang="en">Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2016:CD001800.</mixed-citation></citation-alternatives></ref><ref id="cit255"><label>255</label><citation-alternatives><mixed-citation xml:lang="ru">de Vries H, Kemps HM, van Engen-Verheul MM, Kraaijenhagen RA, Peek N. Cardiac rehabilitation and survival in a large representative community cohort of Dutch patients. Eur Heart J 2015;36:1519-1528.</mixed-citation><mixed-citation xml:lang="en">de Vries H, Kemps HM, van Engen-Verheul MM, Kraaijenhagen RA, Peek N. Cardiac rehabilitation and survival in a large representative community cohort of Dutch patients. Eur Heart J 2015;36:1519-1528.</mixed-citation></citation-alternatives></ref><ref id="cit256"><label>256</label><citation-alternatives><mixed-citation xml:lang="ru">Aldcroft SA, Taylor NF, Blackstock FC, O’Halloran PD. Psychoeducational rehabilitation for health behavior change in coronary artery disease: a systematic review of controlled trials. J Cardiopulm Rehabil Prev 2011;31:273_281.</mixed-citation><mixed-citation xml:lang="en">Aldcroft SA, Taylor NF, Blackstock FC, O’Halloran PD. Psychoeducational rehabilitation for health behavior change in coronary artery disease: a systematic review of controlled trials. J Cardiopulm Rehabil Prev 2011;31:273_281.</mixed-citation></citation-alternatives></ref><ref id="cit257"><label>257</label><citation-alternatives><mixed-citation xml:lang="ru">Janssen V, De Gucht V, Dusseldorp E, Maes S. Lifestyle modification programmes for patients with coronary heart disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol 2013;20:620_640.</mixed-citation><mixed-citation xml:lang="en">Janssen V, De Gucht V, Dusseldorp E, Maes S. Lifestyle modification programmes for patients with coronary heart disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol 2013;20:620_640.</mixed-citation></citation-alternatives></ref><ref id="cit258"><label>258</label><citation-alternatives><mixed-citation xml:lang="ru">Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev 2011:CD008012.</mixed-citation><mixed-citation xml:lang="en">Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev 2011:CD008012.</mixed-citation></citation-alternatives></ref><ref id="cit259"><label>259</label><citation-alternatives><mixed-citation xml:lang="ru">Richards SH, Anderson L, Jenkinson CE, Whalley B, Rees K, Davies P, Bennett P, Liu Z, West R, Thompson DR, Taylor RS. Psychological interventions for coronary heart disease: Cochrane systematic review and meta-analysis. Eur J Prev Cardiol 2018; 25: 247-259.</mixed-citation><mixed-citation xml:lang="en">Richards SH, Anderson L, Jenkinson CE, Whalley B, Rees K, Davies P, Bennett P, Liu Z, West R, Thompson DR, Taylor RS. Psychological interventions for coronary heart disease: Cochrane systematic review and meta-analysis. Eur J Prev Cardiol 2018; 25: 247-259.</mixed-citation></citation-alternatives></ref><ref id="cit260"><label>260</label><citation-alternatives><mixed-citation xml:lang="ru">Rutledge T, Redwine LS, Linke SE, Mills PJ. A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. Psychosom Med 2013; 75: 335-349.</mixed-citation><mixed-citation xml:lang="en">Rutledge T, Redwine LS, Linke SE, Mills PJ. A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. Psychosom Med 2013; 75: 335-349.</mixed-citation></citation-alternatives></ref><ref id="cit261"><label>261</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021-3104.</mixed-citation><mixed-citation xml:lang="en">Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021-3104.</mixed-citation></citation-alternatives></ref><ref id="cit262"><label>262</label><citation-alternatives><mixed-citation xml:lang="ru">Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Sr., Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S, Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomized placebo-controlled trial. Lancet 2018;392:1519-1529.</mixed-citation><mixed-citation xml:lang="en">Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Sr., Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S, Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomized placebo-controlled trial. Lancet 2018;392:1519-1529.</mixed-citation></citation-alternatives></ref><ref id="cit263"><label>263</label><citation-alternatives><mixed-citation xml:lang="ru">Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T, SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844.</mixed-citation><mixed-citation xml:lang="en">Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T, SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844.</mixed-citation></citation-alternatives></ref><ref id="cit264"><label>264</label><citation-alternatives><mixed-citation xml:lang="ru">Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322.</mixed-citation><mixed-citation xml:lang="en">Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322.</mixed-citation></citation-alternatives></ref><ref id="cit265"><label>265</label><citation-alternatives><mixed-citation xml:lang="ru">Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657.</mixed-citation><mixed-citation xml:lang="en">Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657.</mixed-citation></citation-alternatives></ref><ref id="cit266"><label>266</label><citation-alternatives><mixed-citation xml:lang="ru">Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, DECLARE_TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347-357.</mixed-citation><mixed-citation xml:lang="en">Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, DECLARE_TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347-357.</mixed-citation></citation-alternatives></ref><ref id="cit267"><label>267</label><citation-alternatives><mixed-citation xml:lang="ru">Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128.</mixed-citation><mixed-citation xml:lang="en">Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128.</mixed-citation></citation-alternatives></ref><ref id="cit268"><label>268</label><citation-alternatives><mixed-citation xml:lang="ru">Gurfinkel E., Leon de la Fuente R, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) study. Eur Heart J 2004; 25: 25-31.</mixed-citation><mixed-citation xml:lang="en">Gurfinkel E., Leon de la Fuente R, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) study. Eur Heart J 2004; 25: 25-31.</mixed-citation></citation-alternatives></ref><ref id="cit269"><label>269</label><citation-alternatives><mixed-citation xml:lang="ru">Ciczewski A., Bilinska Z.T. et al. Inf luenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD Study. Eur Heart J 2008; 29: 1350-1358.</mixed-citation><mixed-citation xml:lang="en">Ciczewski A., Bilinska Z.T. et al. Inf luenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD Study. Eur Heart J 2008; 29: 1350-1358.</mixed-citation></citation-alternatives></ref><ref id="cit270"><label>270</label><citation-alternatives><mixed-citation xml:lang="ru">Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev 2015(5): CD005050.</mixed-citation><mixed-citation xml:lang="en">Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev 2015(5): CD005050.</mixed-citation></citation-alternatives></ref><ref id="cit271"><label>271</label><citation-alternatives><mixed-citation xml:lang="ru">Caldeira D, Costa J, Vaz-Carneiro A. [Analysis of the Cochrane Review: Influenza Vaccines for Preventing Cardiovascular Disease. Cochrane Database Syst Rev 2015; 5: CD005050]. Acta Med Port 2015; 28: 424-426.</mixed-citation><mixed-citation xml:lang="en">Caldeira D, Costa J, Vaz-Carneiro A. [Analysis of the Cochrane Review: Influenza Vaccines for Preventing Cardiovascular Disease. Cochrane Database Syst Rev 2015; 5: CD005050]. Acta Med Port 2015; 28: 424-426.</mixed-citation></citation-alternatives></ref><ref id="cit272"><label>272</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю., КутишенкоН.П., Калайджян Е.П., Евдаков В.А., Сичинава Д.П. Оценка адекватности выбора лекарственного препарата у больных, перенесших острый инфаркт миокарда, в рамках регистра ПРОФИЛЬ-ИМ. Рациональная Фармакотерапия в Кардиологии 2019;15(2):224-229.</mixed-citation><mixed-citation xml:lang="en">Марцевич С.Ю., КутишенкоН.П., Калайджян Е.П., Евдаков В.А., Сичинава Д.П. Оценка адекватности выбора лекарственного препарата у больных, перенесших острый инфаркт миокарда, в рамках регистра ПРОФИЛЬ-ИМ. Рациональная Фармакотерапия в Кардиологии 2019;15(2):224-229.</mixed-citation></citation-alternatives></ref><ref id="cit273"><label>273</label><citation-alternatives><mixed-citation xml:lang="ru">Хомицкая Ю.В., Аверков О.В., Руда М.Я., от лица исследователей EPICOR-RUS. Долгосрочное наблюдение за подходами к антитромботической терапии у российских пациентов с острым коронарным синдромом: обсервационное исследование (EPICORRUS). Неотложная кардиология 2017;2:23-36.</mixed-citation><mixed-citation xml:lang="en">Хомицкая Ю.В., Аверков О.В., Руда М.Я., от лица исследователей EPICOR-RUS. Долгосрочное наблюдение за подходами к антитромботической терапии у российских пациентов с острым коронарным синдромом: обсервационное исследование (EPICORRUS). Неотложная кардиология 2017;2:23-36.</mixed-citation></citation-alternatives></ref><ref id="cit274"><label>274</label><citation-alternatives><mixed-citation xml:lang="ru">Fox KA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, Avezum A. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur. Heart J. 2002;23(15):1177–1189.</mixed-citation><mixed-citation xml:lang="en">Fox KA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, Avezum A. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur. Heart J. 2002;23(15):1177–1189.</mixed-citation></citation-alternatives></ref><ref id="cit275"><label>275</label><citation-alternatives><mixed-citation xml:lang="ru">Schiele F, Gale CP, Bonnefoy E, Capuano F, Claeys MJ, Danchin N, Fox KA, Huber K, Iakobishvili Z, Lettino M, Quinn T, Rubini Gimenez M, Bøtker HE, Swahn E, Timmis A, Tubaro M, Vrints C, Walker D, Zahger D, Zeymer U, Bueno H.Quality indicators for acute myocardial infarction: a position paper of the Acute Cardiovascular Care Association. Eur. Heart J. Acute Cardiovasc. Care 2017;6:34–59.</mixed-citation><mixed-citation xml:lang="en">Schiele F, Gale CP, Bonnefoy E, Capuano F, Claeys MJ, Danchin N, Fox KA, Huber K, Iakobishvili Z, Lettino M, Quinn T, Rubini Gimenez M, Bøtker HE, Swahn E, Timmis A, Tubaro M, Vrints C, Walker D, Zahger D, Zeymer U, Bueno H.Quality indicators for acute myocardial infarction: a position paper of the Acute Cardiovascular Care Association. Eur. Heart J. Acute Cardiovasc. Care 2017;6:34–59.</mixed-citation></citation-alternatives></ref><ref id="cit276"><label>276</label><citation-alternatives><mixed-citation xml:lang="ru">Simms AD, Batin PD, Weston CF, Fox KA, Timmis A, Long WR, Hall AS, Gale CP. An evaluation of composite indicators of hospital acute myocardial infarction care: a study of 136,392 patients from the Myocardial Ischaemia National Audit Project. Int. J. Cardiol. 2013;170:81–87.</mixed-citation><mixed-citation xml:lang="en">Simms AD, Batin PD, Weston CF, Fox KA, Timmis A, Long WR, Hall AS, Gale CP. An evaluation of composite indicators of hospital acute myocardial infarction care: a study of 136,392 patients from the Myocardial Ischaemia National Audit Project. Int. J. Cardiol. 2013;170:81–87.</mixed-citation></citation-alternatives></ref><ref id="cit277"><label>277</label><citation-alternatives><mixed-citation xml:lang="ru">Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective National Study of the Prevalence, Incidence, Management and Outcome of a Large Contemporary Cohort of Patients With Incident Non􏰅Valvular Atrial Fibrillation. J Am Heart Assoc. 2015;4(1). doi:10.1161/jaha.114.001486</mixed-citation><mixed-citation xml:lang="en">Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective National Study of the Prevalence, Incidence, Management and Outcome of a Large Contemporary Cohort of Patients With Incident Non􏰅Valvular Atrial Fibrillation. J Am Heart Assoc. 2015;4(1). doi:10.1161/jaha.114.001486</mixed-citation></citation-alternatives></ref><ref id="cit278"><label>278</label><citation-alternatives><mixed-citation xml:lang="ru">Lip G, Laroche C, Dan G et al. A prospective survey in European Society of Cardiologymember countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORPAF) Pilot General Registry. EP Europace. 2013;16(3):308-319. doi:10.1093/europace/eut373.</mixed-citation><mixed-citation xml:lang="en">Lip G, Laroche C, Dan G et al. A prospective survey in European Society of Cardiologymember countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORPAF) Pilot General Registry. EP Europace. 2013;16(3):308-319. doi:10.1093/europace/eut373.</mixed-citation></citation-alternatives></ref><ref id="cit279"><label>279</label><citation-alternatives><mixed-citation xml:lang="ru">Sørensen R, Hansen M, Abildstrom S, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. The Lancet. 2009;374(9706):1967-74. doi: 10.1016/s0140-6736 (09)61751-7</mixed-citation><mixed-citation xml:lang="en">Sørensen R, Hansen M, Abildstrom S, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. The Lancet. 2009;374(9706):1967-74. doi: 10.1016/s0140-6736 (09)61751-7</mixed-citation></citation-alternatives></ref><ref id="cit280"><label>280</label><citation-alternatives><mixed-citation xml:lang="ru">Généreux P, Giustino G, Witzenbichler B et al. Incidence, Predictors, and Impact of PostDischarge Bleeding After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2015;66(9):1036-1045. doi:10.1016/j.jacc.2015.06.1323.</mixed-citation><mixed-citation xml:lang="en">Généreux P, Giustino G, Witzenbichler B et al. Incidence, Predictors, and Impact of PostDischarge Bleeding After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2015;66(9):1036-1045. doi:10.1016/j.jacc.2015.06.1323.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
